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ABSTRACT

Discovery of Novel Serum Biomarkers for Diagnosing
and Staging Alzheimer’s Disease
Dipti Jigar Shah
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Alzheimer’s disease (AD) is an untreatable neurologic disease affecting more than 5
million Americans, most over 60 years of age. Protein plaques and neurofibrillary tangles typify
AD brain pathology and are thought to cause the progressive dementia and brain shrinkage
observed in AD. Currently there are no methods to diagnose the disease at a time before damage
becomes irreversible.
Biochemical tests for AD using cerebrospinal fluid analysis or neuroimaging are not yet
sufficiently sensitive and specific, and they are invasive. This points to a need for a more easily
applied and more sensitive diagnostic test. Although the gross anatomical changes are localized
to the brain, AD is likely to involve changes throughout the body. As a result of this, changes in
the abundance of certain biomolecules present in the circulation system are likely to occur.
Consequently, a serum proteomics approach able to measure such changes, when applied to AD,
would likely find quantitative changes in relevant molecules that can help diagnose the disease
correctly, ideally early in the disease process.
The goal of this work was to discover and validate novel diagnostic serum biomarkers for
AD. For biomarker discovery and validation, we used a novel serum proteomics approach
involving reversed phase capillary-liquid chromatography-electrospray ionization-quadrupoletime of flight mass spectrometry. Our samples were protein depleted, which helped us survey
low molecular weight species in the serum without ion suppression from larger proteins like
albumin. We were able to observe more than 8000 molecular species in a single run. The overall
project was comprised of four studies: (i) discovery of novel potential serum AD markers, (ii)
blinded validation of diagnostically promising biomarkers found in the initial study, with their
further chemical identification, (iii) exploring gender-based serum AD biomarkers, and (iv)
discovery of biomarkers that distinguish early versus moderate stage AD.
In the first study, the approach found 38 significant (p < 0.05) biomarkers and 21 near
significant (p = 0.05 to 0.099) biomarkers. On using the forward selection approach, we built
multi-marker panels with specificities and sensitivities higher than 80%.
The second study reports on a blinded validation study that was performed on a new set
of serum samples. We focused on the 13 most promising AD biomarkers found as part of the

initial study. We successfully validated 4 of these biomarkers that showed highly significant
statistical p-values. As part of this study, research was conducted to identify these 4 biomarkers,
which was accomplished using tandem mass spectrometry with fragmentation experiments.
The third study used data from the initial study but looked at gender specific biomarkers.
We found 31 significant and near significant serum AD biomarkers for women, 16 for men, and
25 that were gender independent. Multi-marker panels of AD biomarkers for women or men had
sensitivities of >60% and specificities >85%.
In the fourth study, cases with moderate AD were compared to cases with very mild or
mild AD to find novel biomarkers that could be used for staging. We found 44 significant and
near significant biomarkers that were quantitatively different between mild and severe AD.
In conclusion, we were successful in accomplishing the goal of this work of finding,
validating and identifying novel serum biomarkers that diagnose AD.

Keywords: Alzheimer’s disease, low-molecular weight serum proteome, lipid biomarkers,
gender-based biomarkers, diagnosis, stage comparisons, validation, biomarker identification.
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CHAPTER 1 - INTRODUCTION

1.1 Alzheimer’s Disease (AD)

1.1.1 History
In 1906, German physician Dr. Alois Alzheimer came across a curious case of a 51-year-old
woman, Auguste Deter, in the mental asylum of Frankfurt am Main. The woman was completely
delirious and had alternating versions of reality. She showed jealousy towards her husband and
thought that her life was in constant danger from someone unknown. She screamed for hours at
end and would suffer from auditory hallucinations. Her memory was seriously impaired as well.
She would see certain objects and forget them the next moment. Her reading and writing abilities
had deteriorated to meaningless levels. She no longer remembered the use of certain objects and
was baffled at her surroundings all the time (Stelzmann, Norman Schnitzlein et al. 1995).
After her death, her postmortem showed a uniformly degenerated brain without macroscopic
focal degradation. Depositions of a pathological metabolic substance in or on 67% of all neurons
of the cortex were observed along with entangling and clustering of neurofibrils. These
depositions led to small aggregates distributed all over the cortex with the highest concentration
in the upper layers. Many glial cells showed fibrous outgrowth accompanied by a proliferation of
vessels and a growth on the endothelia. All this led Dr. Alzheimer to believe that this was an
unusual and uncommon illness, and he published his findings in 1907. Emil Kraepelin, Dr. Alois
Alzheimer’s mentor in Munich, finally named this illness “Alzheimer’s disease” in 1910
(Stelzmann, Norman Schnitzlein et al. 1995, Small and Cappai 2006).

1

1.1.2 Pathology and Research Progress
The post-mortem findings of Dr. Alzheimer were the stepping-stone to highlight the
pathological and neurological effects of AD in the patient’s brain. In an AD brain, plaques are
found outside the brain cells while neurofibrillary tangles are seen inside the brain cells. Plaques
interrupted synapses, breaking the signals between the brain cells. Tangles damage brain cells by
obstructing the transport of food and energy around the brain cells. Thus, progressive memory
loss and brain degeneration are hallmarks of AD. Despite these consistent anatomical changes,
there are no approved ways to diagnose the disease in time for effective treatment and
appropriate dietary supplementation.
More than a century later, vast advances have been made to the understanding of this dreaded
disease. The pathological and neurological effects of AD have been well documented although
methods are still being researched to provide an early diagnosis that may allow for treatments to
be tested with the hope that they will be able to prevent or slow down the disease in the long
term. The progress made in the research of Alzheimer’s is traced chronologically in Table 1.1.

1.1.3 Prevalence and Impact
Despite all of the research, AD is the most common form of dementia and affects 20-30
million people worldwide. In the US alone, one out of nine develops AD and over 5.2 million
people in the US already suffer from AD as of 2013. The number is predicted to grow to 13.8
million by 2050. AD is the sixth leading cause of death in the country and AD fatalities have
increased 68% between 2000 and 2010. In that same period, deaths attributed to heart disease,
which is the number one cause of death in the country, have decreased 16% (German, Gurnani et
al. 2007, Association 2013).

2

Table 1.1. Summary of the history of research into Alzheimer’s disease and related disorders.
Reprinted from (Hardy 2006, Blennow 2011) with permission. © Elsevier, 2006 and Macmillan
Publishers Ltd., 2011.

Year
1902

Related Developments

Alzheimer's Disease

Improved silver stains

1906

Alzheimer’s case history of Auguste Deter

1910

Alzheimer’s disease named

1922

Lewy body described

1932
1962

First hereditary case described
L-dopa therapy in Parkinson's
disease (Mayeux, Honig et al.)

1964
1968

Ultrastructure of plaque and tangle by electron
microscopy
Recognition of prevalence of disease in the elderly

1976

Cholinergic deficit described

1983

Huntington's genetic linkage

1984
1985

Cloning of the prion gene

Sequence of Amyloid-β (Aβ) from AD amyloid
angiopathy
Sequence of Aβ from Down's syndrome from
amyloid angiopathy
Sequence of Aβ from plaques

1986

Tau as major component of tangles

1987

Cloning of amyloid precursor protein (APP) and
localization to chromosome 21

1989

1990

1991

Mutations in prion gene in
Creutzfeldt-Jakob
Disease (CJD)/ GerstmannSträussler-Scheinker disease (GSS)
Mutations in APP cause hereditary
cerebral hemorrhage with
amyloidosis-Dutch type
(HCHWA-D); prion mutations
cause neurodegeneration in mice

1994

APP mutations in AD; a descriptive system of
cataloguing the neuropathology determined
Apolipoprotein E-ε4 gene (ApoE4) associated with
AD; cholinergic therapy approved for AD
APP mutations increase Aβ42

1995

APP transgenic mice made with plaque pathology;

1993

3

presenilins cloned as loci for early onset AD
1996
1997
1998

Presenilin mutations shown to alter APP processing
Synuclein mutations identified in
PD; Synuclein identified as major
component of Lewy bodies
Tau mutations identified in
Frontotemporal dementia with
parkinsonism-17 (FTDP-17)

1999
2000

Presenilins identified as γ-secretase
Beta-secretase cloned; Aβ immunization in mice
reduces amyloid pathology

Mice with tangles made using
FTDP-17 mutations

2001

Mice with plaques and tangles made

2003

Aβ vaccine trials halted because of side effects

2004

Pittsburgh Compound B (PIB) positron electron
tomography (PET) ligand shown to bind to fibrillar
brain Aβ
Dubois's research criteria for AD (biomarker-based
criteria, independent of dementia) published.
Dubois's lexicon defining AD (preclinical AD,
prodromal AD, AD with dementia) published;
cerebrospinal fluid (CSF) assay for Aβ oligomers
developed

2007
2010
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Another notable aspect to the statistics on AD are the number of caregivers. In 2012, 15
million family members and voluntary caregivers gave 17.5 billion hours of their time to care for
patients with AD and other mental illnesses, a contribution worth more than 216 billion dollars.
Apart from this valuation, the total payments made to health care professionals, hospitals,
medical treatments, long term care and hospice services for AD patients came out to be 203
billion dollars for 2013. All this doesn’t take into account the mental and physical stress the
caregivers go through. For family caregivers, to see a loved one go through memory loss,
functional decline and mental outbursts is emotionally devastating. It starts taking a toll on their
health too, increasing their own risk of chronic diseases and stress related disorders (Association
2013).

1.2 AD Biomarkers
Development of medical therapies for AD has been difficult because subjects with earlier
stage disease cannot be radiologically or biochemically identified. Over the last decade, there has
been substantial research done on identifying biomarkers that would aid in early diagnosis of AD.
The research can broadly be categorized into the following fields: genomics, proteomics,
structural and functional imaging and neurophysiology (Cedazo-Minguez and Winblad 2010)
The defining characteristics of an ideal biomarker is as follows:
1. A biomarker must dependably differentiate pathological cases from normal subjects at an
early stage of the disease.
2. The patient should incur the least (possible) discomfort, risk and attendant expenses so
that more samples can be collected to allow serial research studies to observe various
stages of the disease as it progresses.
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3. The biomarker must undergo uniform validation in various populations of AD patients.
4. The biomarker should be able to forecast the emergence of psychological symptoms and
should be validated in potential clinical trials (preferably with follow-up to postmortem.to
allow concrete diagnosis).
The current status of all biomarkers for AD to date is summarized in the following sections.

1.2.1 Inflammatory Biomarkers
AD brains exhibit evidence of inflammatory processes. A serine protease inhibitor, α1antichymotrypsin (ACT), that is found associated with Aβ in senile/neuritic plaques, is a
thoroughly researched inflammatory marker. Preliminary studies of ACT have yielded variable
results from unchanged ACT to increased ACT in AD serum or CSF. Further studies that
involved a larger sample population concluded an overall increase in the plasma and CSF ACT
levels of patients with AD, and an inverse correlation between the levels and cognitive
capabilities. The general consensus was that increased levels of ACT signified increased risk of
dementia, vascular dementia (Fjell, Walhovd et al. 2010) and AD but was not able to
differentiate between the different types of dementia (Nielsen, Minthon et al. 2007).
The findings from cytokine studies for AD patients have been inconclusive as well.
Independent studies have found mixed results for CSF and plasma/serum interleukin-6 (IL-6)
levels in AD patients and also the use of their levels to differentiate between VD and AD. These
results have been attributed to the basic challenges faced in the evaluation of cytokines in AD
because cytokine concentration changes significantly over time and can vary based on the
individual’s genetic background, multiple inflammatory processes in the system, antiinflammatory drugs use and environmental factors (Craig-Schapiro, Fagan et al. 2009).
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1.2.2 Genetic Biomarkers
An alternative approach to identifying biomarkers in mental disease is the use of
transcriptional profiling of genes in patient samples. This approach can potentially predict
changes at a much earlier stage than changes observed for protein alterations. Also, the
uniformity of whole blood RNA allows transcriptome studies to be done easily compared to both
proteome and metabolic studies. Initial studies of AD patients compared with controls found 20
genes out of 3200 that showed a different expression. The expression patterns of 33 genes which
included APP, insulin degrading enzyme, histone cluster 1, H3e (HIST1H3E) and cannabinoid
receptor 2 (CNR2) were further studied over a period of one year in correlation to AD. The
results demonstrated a negative correlation of HIST1H3E and a slight positive correlation of
CNR2 to the Mini-mental State Examination (MMSE) score. These results hold out promise of
gene expression profiling as a way to find biomarkers for early AD (Cedazo-Minguez and
Winblad 2010).

1.2.3 Neuroimaging Biomarkers
Functional and molecular neuroimaging have shed light into brain structure and physiology.
This has permitted investigation of specific proteins and aggregates. This is hard to achieve even
via brain autopsy. For instance, the distinctive type of degeneration in cortical and hippocampal
areas in cases of severe AD are difficult to quantify even during an autopsy. Nevertheless, the
biggest drawback is that brain atrophy cannot be measured until the latter stages of the disease
when it appears. Additionally, neurodegeneration and cognitive decline are also found in other
brain diseases and tissue volume changes in the brain are not indicative of the pathology of the
disease. In the end, all the information on brain degeneration and volume changes in late stage
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AD cannot be used to any real advantage if it does not make early stage, ante-mortem analysis
possible (Perrin, Fagan et al. 2009).
There have been efforts to make neuroimaging more sensitive and more specific. Among the
five dyes: [18F]FDDN, 18F-BAY94-9172, 11C-SB-13, 11C-BF-227 and 11C-PIB used to date
for imaging Aβ plaques, only [18F]FDDNP may be retained by neurofibrillary tangles (Small
and Cappai 2006). As yet, no compound that selectively binds to aggregates of tau has been
found (Perrin, Fagan et al. 2009). When microglia go through changes with activation, the
expression of benzodiazepine receptors increases. Thus, it can be utilized as a target for
radiological compounds like [11C]DAA1106 (Zhang, Maeda et al. 2004), [11C]vinpocetine (Vas,
Shchukin et al. 2008) and [11C](R)-PK11195. Only the last of these has been reported in studies
of Alzheimer's disease in humans, in conjunction with PIB (Perrin, Fagan et al. 2009). Their
value then is largely unknown.

1.2.4 Neurophysiological Biomarkers
During the transition between healthy aging and AD, various quantitative
electroencephalography (qEEG) components, as well as event related potential (ERP) activity,
are altered. For example, anomalies in P600 and N400, two ERP components, link the
conversion from memory loss related MCI to AD. A vagus nerve stimulation (VNS) technique
was recently established to attempt early diagnosis of dementia. The consideration of these
markers is important because of their simplicity and cost-effectiveness in identifying early AD
patients that would allow timely measures to be taken (Cedazo-Minguez and Winblad 2010).
However, at this time these tests are not applied generally.
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1.2.5 Tissue Biomarkers
Amyloid-β is a peptide fragment of amyloid precursor protein produced by sequential
activities of the β-secretase and γ-secretase enzymes. It shows up in different lengths with amino
acid residues ranging from 38 to 43. The peptides most frequently involved in the formation of
plaques associated with AD are Aβ40 and Aβ42. In addition, other proteins are associated with
the neurofibrillary tangles that are also seen in AD. The two most common are tau and
phosphorylated forms of tau, and these have emerged as chief diagnostic and prognostic CSF
biomarkers. The amyloid cascade hypothesis of AD considers Aβ42 as the central peptide
leading to Aβ aggregation (Hardy and Selkoe 2002, Perrin, Fagan et al. 2009).

1.2.6 CSF Biomarkers
Because the cerebrospinal fluid communicates with aspects of the brain, the same proteins as
described in the preceding section have been investigated as biomarkers for AD. Some of the
well-documented changes in these amyloid peptides in patients with diagnosed AD include
decreased CSF levels of the 42-amino acid beta amyloid peptide (Aβ 42). This is thought to
indicate a change from a soluble form in the CSF to its accumulation and aggregation in plaques
in the central nervous system. Initial studies of APP levels were too varied to be considered
useful as a potential biomarker for AD. Also, elevated CSF levels of microtubule-linked protein
tau are considered a generic indicator of brain damage, but the hyperphosphorylation of tau that
seems to be observed mostly in the brains of AD patients makes increased CSF levels of
phosphorylated tau (p-tau) a more promising and specific indicator for AD. These markers are
used commercially to aid in AD diagnosis. Reduced levels of CSF Aβ 42, increased total tau (ttau) and tau phosphorylated at residue 181 (p-tau181) have the potential to be an early diagnostic
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indicators of AD in persons with mild cognitive impairment (Okonkwo, Mielke et al. 2011).
These findings also suggest that AD pathological degradation starts much earlier than dementia.
It’s still being determined as to when these CSF alterations actually take place during the early
phases of AD before the symptoms set in. The challenges faced are in the procurement of
samples from normal, middle-aged people who will eventually develop AD in their older age
(Ringman, Coppola et al. 2012).

1.2.7 Conclusions
The only conclusive diagnosis of AD is post-mortem microscopic examination of the brain.
At present, AD diagnosis includes detailed assessment of the patient’s personal and family
medical histories and administering neuropsychological tests to evaluate cognitive function, as
well as precluding other sources of dementia such as vitamin and mineral deficiencies, low
thyroid function, infections, cancer and depression and excluding possibilities of other braindegenerative dementias like frontotemporal, Lewy-body and CJD.
Brain imaging and CSF can assist in discriminating later stage and potentially earlier stage
AD from other dementias and neurodegenerative disorders. This conclusion is based on the
evidence that the AD brain has damaged and/or affected learning and memory areas, shows
atypical deposits of Aβ plaques, accumulation of apoE and neurofibrillary tangles (NFTs) of
protein tau and α-synuclein, and is characterized by diminished glucose metabolism. CSF testing
shows decreased concentrations of Aβ peptides and increased concentration of tau protein in
cases of AD, although this is often in later stage AD (Mucke 2009). While NFTs and Aβ plaques
typify the disease, they do not entirely characterize AD. Neuronal, axonal and synaptic
impairment/loss together with inflammation may be even earlier events in the disease process,
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some believing they start decades before the first symptoms of Alzheimer’s surface (Braak and
Braak 1997, Perrin, Fagan et al. 2009, Price, McKeel Jr et al. 2009). NFTs and Aβ plaques occur
only about 10-15 years before the neurons of the hippocampus and medial temporal lobe are
wiped out, leading to the onset of the clinically significant cognitive decline (Petersen, Doody et
al. 2001, Perrin, Fagan et al. 2009). Most of the tests, including imaging and CSF testing, used to
diagnose AD biomarkers, cannot accurately predict disease before substantial damage is present.
In a disease like AD, this provides little value.

1.2.8 Why Blood Biomarkers
Over the last 10 years, increasing focus has been placed on blood-based biomarkers. The
CSF biomarkers and neuroimaging techniques are sensitive and accurate. Aβ-42, total tau and
hyperphosphorylated tau proteins in cerebrospinal fluid are specific AD biomarkers with
moderate sensitivity that can differentiate people with MCI who progressed to AD and who did
not. However, there are limitations to clinical implementations of these techniques. The lumbar
puncture technique for CSF sample collection is considered invasive and has become unpopular
in several countries. Also, collecting samples at different stages of the disease is often not
possible, which impacts monitoring (Henriksen, O’Bryant et al. 2014).
Hence, blood biomarkers would have a distinct advantage compared with CSF biomarkers
because of the relative ease of collecting samples. Also, these samples can be regularly obtained
at a hospital or the residence of the patient to enable economically viable checkups and stage-bystage monitoring of the disease (Lista, Faltraco et al. 2013). Because of this, early diagnosis of
AD may become possible which will benefit efforts to find better treatment and improve the
lives of the patients. This is especially critical since AD is becoming more and more globally
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prevalent.

1.2.9 Current Blood Biomarkers
Biomarkers in plasma for AD have been researched for the last decade but have not yielded
consistent results because of the limitations imposed by the blood brain barrier (BBB). Proteins
and metabolites from the brain often have limited and variable access to the general circulation,
and even if they cross the BBB, they become significantly diluted when they enter the plasma. It
is hard to detect biomarkers closely linked to brain pathology, including small metabolites,
lipophilic molecules and even molecules with specific transporters. These biomarkers appear to
differ from person to person. A conscious effort has been made to focus most of the research on
measuring the disease-specific molecules, which in AD’s case is beta-amyloid (Aβ). Total
plasma Aβ or Aβ-42 levels are found to be elevated in inherited AD, but inconsistency in the
results allowed only poor diagnosis of AD. Another reason for the inconclusive evidence is that
there are other sources of Aβ such as platelets which make Aβ in plasma a non-tissue specific
marker. Studies have also shown that simultaneous use of medications, including insulin, also
affects the concentration of Aβ in plasma (Cedazo-Minguez and Winblad 2010). Many research
studies have been done to find proteomic-based biomarkers. Table 1.2 lists the biomarkers found
to date.

1.3 Proteins and Lipids as Biomarkers

1.3.1 Proteomics
The word proteome was first used to classify a set of proteins in a genome in a particular
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Table 1.2. Serum biomarkers for AD (*Serum proteomics studies, **Only when AD only and AD
with cerebral amyloid angiopathy (CAA) are combined, NEV = No estimate of variance). (Source:
Zabel, Schrag et al. 2012).
Identified protein

Protein
function

Publications

Alpha2macroglobulin

Protease
inhibitor

(Giometto, Argentiero et al.
1988)
(Licastro, Morini et al.
1995)
(Licastro, Parnetti et al.
1995)
(Zhang, Barker et al. 2004)

Alpha1antichymotrypsin

Protease
inhibitor

Reported
change in
AD (initial
finding)
No change

Increased

p = 0.02

Trend
toward
increase

p = 0.14

No change
No change
↑ NEV

(Hye, Lynham et al. 2006)

↑ p = 0.006

(Hye, Lynham et al. 2006)

↑ p = 0.001

(Cutler, Akuffo et al. 2008)

No change

(Matsubara, Amari et al.
1988)

↑ p < 0.001

(Matsubara, Hirai et al.
1990)
(Brugge, Katzman et al.
1992)
(Hinds, Kukull et al. 1994)

↑ p < 0.001

(Licastro, Morini et al.
1995)
(Licastro, Parnetti et al.
1995)
(Lieberman, Schleissner et
al. 1995)
(Altstiel, Lawlor et al.
1995)
(Licastro, Pedrini et al.
2000)
(Licastro, Pedrini et al.
2000)
(McIlroy, Vahidassr et al.
2000)
(DeKosky, Ikonomovic et
al. 2003)
(Nielsen, Minthon et al.
2007)

↑ p < 0.001
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Current result (LCMS/MS follow up
results)

↑ p < 0.05
↑ p < 0.05

↑ p < 0.01
↑p<
0.00001
↑ p < 0.001
↑ p < 0.0001
↑ p < 0.001
↑ p < 0.001
↑ p = 0.01
↑ p < 0.0.05

Alpha1antitrypsin

Complement C3

Complement C4

C1 inhibitor

Complement
factor H

Serum amyloid P

CD5 antigen

Protease
inhibitor

Inflammation

Inflammation

Complement
regulation

Complement
regulation

Immune
regulation
Immune
regulation

(Porcellini, Davis et al.
2008)
(Furby, Leys et al. 1991)

↑ p < 0.0001

(Pirttila, Mehta et al. 1994)

No change

(Zhang, Barker et al. 2004)

No change

(Cutler, Akuffo et al. 2008)

No change

(Giometto, Argentiero et al.
1988)
(Matsubara, Amari et al.
1988)
(Licastro, Morini et al.
1995)
(Licastro, Parnetti et al.
1995)
(Nielsen, Minthon et al.
2007)
(Cutler, Akuffo et al. 2008)

↑ p < 0.001

(Liao, Yu et al. 2007)

↑ p = 0.0003

(Giometto, Argentiero et al.
1988)
(Zhang, Barker et al. 2004)

↑ p < 0.005

(Cutler, Akuffo et al. 2008)

No change

(Giometto, Argentiero et al.
1988)
(Zhang, Barker et al. 2004)

↑ p < 0.005

(Hye, Lynham et al. 2006)

↓ p = 0.021

(Cutler, Akuffo et al. 2008)

No change

(Zhang, Barker et al. 2004)

↑ NEV

(Cutler, Akuffo et al. 2008)

↑ p = 0.017

(Cutler, Akuffo et al. 2008)

↑ p = 0.029

(Zhang, Barker et al. 2004)

↑ NEV

(Hye, Lynham et al. 2006)

↑ p = 0.001

(Cutler, Akuffo et al. 2008)

No change

(Hye, Lynham et al. 2006)

↑ p = 3E-04

(Verwey, Schuitemaker et
al. 2008)
(Hye, Lynham et al. 2006)

No change
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No change

No change

p = 0.65

Increased

p = 0.06

Increased

p = 0.004

Trend
toward
increase

p = 0.035

No change

p = 0.567

No change

p = 0.567

No change

p = 0.298

No change
No change
No change
No change
No change

↑ NEV

↑ NEV

↓ p = 0.029

Ceruloplasmin

Transthyretin

Clusterin

(Giometto, Argentiero et al.
1988)
(Licastro, Morini et al.
1995)
(Kessler, Pajonk et al.
2006)
(Squitti, Quattrocchi et al.
2006)
(Squitti, Ventriglia et al.
2007)
(Cutler, Akuffo et al. 2008)

↑ p < 0.001

(Zhang, Barker et al. 2004)

↑ NEV

(Cutler, Akuffo et al. 2008)

No change

Lipid transport (Cutler, Akuffo et al. 2008)

↑ p = 0.019

Copper
chaperone

Thyroxin/retin
ol transport

No change

p = 0.717

Trend
toward
increase

p = 0.182

No change

p = 0.243

No change

p = 0.243

No change
↓ p = 0.015
No change
No change
No change

No change
(Liao, Yu et al. 2007)

↓ p = 0.0004
↓ p = 0.0061

Apolipoprotein
A-1

Apolipoprotein
B100
Apolipoprotein E

Gelsolin
Vitamin Dbinding protein
Inter-alphatrypsin inhibitor

Lipid transport (Zhang, Barker et al. 2004)

No change

(Liu, Hu et al. 2006)

↑ p < .0002

(Cutler, Akuffo et al. 2008)

No change

Lipid transport (Zhang, Barker et al. 2004)

↑ NEV

No change

p = 0.616

Lipid transport (Scacchi, Gambina et al.
1999)
(Zhang, Barker et al. 2004)

No change

No change

p = 0.545

(Cutler, Akuffo et al. 2008)

No change

(Cutler, Akuffo et al. 2008)

No change

No change

p = 0.656

(Liao, Yu et al. 2007)

↑ p = 0.0015

No change

p = 0.346

(Matsubara, Amari et al.
1988)
(Liao, Yu et al. 2007)

No change

Increased*
*

p = 0.031

Actin-binding
protein
Vitamin D
metabolite
transport
Acute Phase
Protein

↑ NEV

↑ p = 0.0016
↑ p = 0.0045
↑ p = 0.0030
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time and space. The composition of these proteins varies from cell to cell and tissue to tissue and
is dependent on various cellular conditions such as pH. The primary structure is of course the
specific amino acid sequence encoded by a specific gene, although on occasion there can be
splice variants of a single gene and there are frequently somewhat variable numbers and types of
post-translational modifications (PTMs). These factors account for the very large number of
unique proteins observed compared to the number of their equivalent genes. These reasons mark
both the potential and challenge in the consideration of proteins to be biomarkers for the
diagnosis and staging of neurodegenerative diseases (Lista, Faltraco et al. 2013).
This comparatively novel approach to finding biomarkers has diverged from the more
traditional approach of investigating only those molecules believed to play a role in the
pathology of AD. Current proteomic approaches for biomarker discovery use an unbiased, global
profiling of proteins expressed in bodily fluids to discover new biomarkers.

1.3.1.1 Studying Low Molecular Weight Serum Proteins Using Approaches That Involve
High Abundant Protein Depletion
Protein depletion strategies reduce the dynamic range and complexity of serum proteins to
enable detection of low abundance molecules. After precipitating high abundance serum proteins,
success has been reported in the observation of approximately 10,000 (representing a possible
majority of the blood proteome) different lower molecular weight, low abundance peptide
disease markers, which are highly indicative of an underlying cell or tissue state (Adkins,
Varnum et al. 2002, Tirumalai, Chan et al. 2003, Ray, Reddy et al. 2011). These may often be
generated from proteolytic cleavage of larger molecules in blood (Davis, Auger et al. 2007).
Albumin, the most abundant large protein in blood routinely acts as a carrier protein to
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transport physiologically crucial biomolecules like hormones, cytokines and lipoproteins
(Tirumalai, Chan et al. 2003, Veenstra, Conrads et al. 2005). Hence, many of these low abundant,
low molecular weight proteins in serum form biomarker-carrier complexes by non-covalent
linkage with large proteins (Tirumalai, Chan et al. 2003, Chertov, Biragyn et al. 2004, Araujo,
Petricoin et al. 2008). This process facilitates clearing of unbound low abundance smaller
biomarkers in the bloodstream through the kidneys while larger carrier proteins and bound
smaller peptides are generally not filtered or are much more gradually eliminated from the body
(Araujo, Petricoin et al. 2008).
To avoid ion suppression by larger proteins in the mass spectrometer system, prior depletion
of these large proteins is necessary. This helps study the low abundance and low mass molecular
species in serum (Ray, Reddy et al. 2011). Now, since several of the small and low abundance
proteins/peptides of interest may be in a complex with large carrier proteins, specific
methodologies must be undertaken to curtail biomarker loss during protein depletion
experiments.
Formerly, a variety of protein depletion methods have been used. Some of these include: 1)
employing antibody-based affinity columns to selectively remove the most abundant serum
proteins including albumin, haptoglobulins, transferrins, α-1-antitrypsin, α-1-acid glycoprotein,
hemopexin, and α-2-macroglobulin (Tirumalai, Chan et al. 2003, Chertov, Biragyn et al. 2004,
Veenstra, Conrads et al. 2005); and 2) use of solid phase extraction involving dye-ligand binding,
antibody-based, metal chelating, and ion-exchange techniques (Ray, Reddy et al. 2011).
Notwithstanding the commercially available protein depletion apparatuses, the important point is
that an ideal depletion approach should eliminate highly abundant proteins as well as lead to the
dissociation of low abundance, smaller peptides from carrier proteins (Tirumalai, Chan et al.
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2003). This is not the case with the above approaches.
Centrifugal ultrafiltration has been commonly used in the area of proteomics in the past. It
did not necessarily involve use of specific solvent conditions to unlink large protein-biomarker
complexes. Besides, use of molecular weight cutoff filters restricts analysis to the low molecular
weight proteome, lower than a specific molecular weight cut-off (Tirumalai, Chan et al. 2003).
Hence, the risk remains of losing some important molecules that are larger than the cut-off filter
and pore size (Merrell 2009, Alvarez 2013).

1.3.1.2 Rationale for Acetonitrile Precipitation
A traditional protein precipitation method uses an organic solvent, e.g., acetonitrile. It has
been reported to effectively precipitate large molecular weight, highly abundant proteins such as
serum albumin (Chertov, Biragyn et al. 2004). Research has shown that acetonitrile also disrupts
the bond between small molecules and large proteins, thus allowing the peptides and small
proteins to be visible during mass spectrometric analysis; it is greatly superior to other
approaches (Merrell, Southwick et al. 2004, Alvarez 2013).
In previous studies done in my lab, experiments were conducted to study the effect of
acetonitrile precipitation on serum proteins. Comparisons were made between untreated cLC-MS
chromatograms and those treated with acetonitrile. The results demonstrated that the posttreatment total-ion chromatogram (TIC) had increased numbers of molecular species compared
to pre-treatment ones. Panels A and B in Figure 1.1 show the difference clearly. Also the mass
spectrum of the untreated serum protein (Panel C) shows an encompassing band that has peaks
between 1300-1400 that signifies higher molecular weight species such as albumin or related
compounds (60-70 kDa), thereby obscuring many molecular species. A larger number of species
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can also be seen in regions of lower m/z (Panel D) that further confirms that organic solvent
precipitation of serum proteins releases smaller, protein-bound species. Although the higher
molecular weight species in the serum are lost by the acetonitrile treatment, Panel E shows that
highly abundant albumin can also create the same effect, i.e., mask the larger proteins. Also, as
seen in Panel C and D, acetonitrile treatment results in a larger number of smaller proteins of low
molecular weight that are more observable. Also, considering the fact that the majority of growth,
regulatory, stimulatory and pathology-responsive factors are small proteins, the probability of
finding valid disease biomarkers increases after these treatments that reveal the smaller
molecular species. In summary, acetonitrile pretreatment allows a wider spectrum of proteins and
peptides in serum to be studied that in turn can increase the likelihood of discovering diagnostic
patterns and informative biomarkers.

1.3.1.3 Uniqueness of This Approach
There was something regarding this method that I had not initially realized. In addition to the
low molecular weight protein/peptide molecules, it also provides access to low molecular weight
lipid molecules. These were mainly focused in the latter half of the useful chromatographic
region. Many of these were glycerophospholipids and their oxidation products, because most
other lipid classes do not easily become ionized without adding adducts to the processed
specimens. These have proven to be reproducible and very important biomarkers during the
course of my study. Since the approach involves lipids and specifically glycerophospholipids as
well, the next section will focus on them and their usefulness as biomarkers.
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Figure 1.1. Comparison between (1 μg) non-protein depleted serum samples and acetonitrile (ACN)
treated protein depleted samples. A: total ion chromatograms (TIC) for serum proteins without
protein depletion, B: TIC for acetonitrile precipitated sample, C: averaged mass spectra for the
cLC elution taken from 24 to 25 min of a serum specimen prior to ACN precipitation, D: same as C
but collected post ACN precipitation, and E: overlay of the mass spectra for species present
between 25 and 26 min of elution for the two samples. Before ACN precipitation is shown in blue,
after ACN precipitation is shown in red. Reprinted from (Merrell 2009) with permission. ©Karen
Merrell, 2009.
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1.3.2 Lipidomics
Lipidomics involves study of the molecular species of lipids and their distinguishing
characteristics (Carrasco-Pancorbo, Navas-Iglesias et al. 2009). This field has attracted growing
interest in the past few years. The interest has been fueled by the increased knowledge of how
lipids interact with the body’s physiology and pathology, and progress made in the analytical
instrumentation area that has enabled fast and extensive analysis.

1.3.2.1 Glycerophospholipids
The plasma membrane of every living cell is composed of phospholipids [also called
glycerophospholipids (GPLs)], carbohydrates, proteins and cholesterol. The main element of the
membrane, however, is GPLs. They are amphipathic in nature and have non-polar acyl chains
attached to their polar head groups, which characterize the lipid subgroup or class. The polar
head group has a phosphate group esterified to the sn-3 position of a glycerol backbone (Schiller,
Süß et al. 2004). Phosphatidylcholine, phosphatidylethanolamines, phosphatidylserines,
phosphatidylinositols and phosphatidylglycerols are the major head group classes (Wolf and
Quinn 2008). Long-chain fatty acids, 14-24 carbons in length, acylate or alkylate the glycerol
backbone at the sn-1 and sn-2 positions. Esterification of saturated or monounsaturated fatty
acids is found in the sn-1 position of the glycerol backbone, and of polyunsaturated fatty acids
(PUFAs) in the sn-2 position (Hermansson, Hokynar et al. 2011). The structural variety caused
by the varying fatty acids and head groups leads to hundreds of lipid molecules (Figure 1.2).
Fahy et al. published a complete classification system for lipids, thereby establishing a
general nomenclature (Fahy, Subramaniam et al. 2005). The classification of
glycerophospholipids is done based on their polar head group and location of fatty acid residues.
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Figure 1.2.
Structures
of the different
Glycerophospholipids.
Reprinted
from (Carter
Figure
1.5. Structures
of the classes
differentofclasses
of Glycerophospholipids
according
to their
2011) with permission. ©Claire Louise Carter, 2011.

polar head group, drawn in green, with the glycerol backbone in blue, R1 and R2
represent acyl chains.

A comprehensive classification system for lipids was published in 2005 by Fahy et al to
establish a universal nomenclature for lipids[142]. From this glycerophospholipids are
recognised by their polar head group and type and location of their fatty acid residues. For
instance, a choline containing head group will be termed a glycerophosphocholine, or
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  contained palmitic acid (hexadecanoic acid)
simply phosphatidylcholine, if sn-1 and sn-2

and arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid) respectively, would have a

Therefore, a choline at the head group will be termed a glycerophosphocholine. It would be
termed a phosphatidylcholine, and if sn-1 and sn-2 contained palmitic acid (hexadecanoic acid)
and arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid), respectively; this lipid would have
a systemic name of 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3phosphocholine, called PC(16:0/20:4(5Z,8Z,11Z,14Z)), which can then be further abbreviated to
PC 36:4 (Figure 1.3).
GPLs are plentiful in cellular systems. Singer and Nicholson published the fluid mosaic model
for cell membranes in 1972, where the membrane is a sandwich of phospholipids (Singerand
Nicolson 1972). GLPs were initially assumed to be membrane barriers and sources of energy, but
are now understood to interact with multiple physiological processes like cell signaling
(Hermansson, Hokynar et al. 2011). GPLs hydrolyze the poly-unsaturated fatty acids (PUFAs),
which are further metabolized into various biologically functional molecules. Figure 1.4 shown
above displays the fluid mosaic model of the cell membranes as well as a summary of lipid
involvement in physiological processes. Lipid prevalence has been found to be changed in very
many pathological conditions like diabetes, Alzheimer’s, cancer, heart diseases, etc. (Kawata,
Chitranukroh et al. 1987, Williams, Coleman et al. 1991, Vered, Eugenio et al. 1993, Montine,
Neely et al. 2002, Fathi, Isbel et al. 2004, Cunnane, Plourde et al. 2009, Florent-Béchard,
Desbène et al. 2009, Gorjão, Azevedo-Martins et al. 2009, Huwiler and Pfeilschifter 2009, Beel,
Sakakura et al. 2010, Han 2010, Reed 2011). Studies need to be done to understand the
consistency of these changes as potential biomarkers for diseases (Carter 2011).
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Figure 1.3. Structure of 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero- 3phosphocholine, commonly known as PC 36:4. Reprinted from (Carter 2011) with permission. ©
Claire Louise Carter, 2011.
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Figure 1.7 Schematic representation of the fluid mosaic model of cell membranes,
Figure
1.4. Schematic
representation
of the fluid
mosaic
model of144-146].
cell membranes. Reprinted from
adapted
from[143],
addition information
collected
from[108,
(Carter 2011, Singer and Nicolson 1972) with permission. ©Claire Louise Carter, 2011; American
Association for the Advancement of Science, 1972. Additional information was obtained from

With the involvement of lipids in numerous physiological processes it is unsurprising that
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distribution
has also been
shown to be altered in a number of pathological conditions.
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These include, diabetes, Alzheimer’s, cancer, heart disease, and numerous metabolic
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diseases, and the list is still growing [108, 144-154]. It is yet to be understood as to

1.4 Mass Spectrometry Based Biomarker Discovery

1.4.1 General Workflow
Enormous advances in mass spectrometry (MS) techniques have made proteomics a potent
tool to discover biomarkers. The initial steps in the process have generally included collecting
samples and separating proteins by means of two dimensional gel electrophoresis (2-DE), liquid
chromatography (LC) or protein-chip arrays. The next steps are to analyze the samples using MS
or tandem MS and then making database searches to identity the protein (Craig-Schapiro, Fagan
et al. 2009). This is summarized in Figure 1.5.
Figure 1.5 outlines the workflow for biomarker investigation in plasma/serum samples using
global mass spectrometry. The first step involves having appropriate, carefully collected samples
from well-documented patients and controls. These samples are then processed to remove
proteins that are highly abundant or the proteins are separated into convenient size ranges using
gel chromatography (Rami, Gomez-Anson et al. 2007), LC or high performance liquid
chromatography (HPLC). The second step then is to identify proteins that are quantitatively
different between the samples of the patients and controls using one or more mass spectrometry
platforms or databases. Once a panel of potential biomarkers has been identified, the third step is
to validate them, to define the ones that can be used for clinical diagnosis. Independent analytical
approaches are preferable for validation studies such as antibody-based techniques like enzymelinked immunosorbent assay (ELISA) or western blotting (Rappeport, Parkman et al. 1980) that
are well known for their high sensitivity (Lista, Faltraco et al. 2013).
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Figure 1.5. Workflow for biomarker investigation in plasma/serum samples using global mass
spectrometry. Reprinted from (Lista, Faltraco et al. 2013) with permission. ©Elsevier, 2013.
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1.4.2 My Approach
Specifically related to research on AD, diagnostic biomarkers are being researched in two
different ways. The first way is the traditional way of trying to analyze biomarkers based on the
understood neuropathology of AD. While this approach is intuitive, it always has some amount
of bias to it since the discovery process is limited to assumptions based on the currently available
data regarding AD. The second way uses the technological advances in MS by calculating
differences in protein/peptide masses in the samples of patients and controls for all detectable
species. The advantage of this approach is that it’s an impartial and independent method that
doesn’t take any preconceived notions into consideration and, therefore, gives an opportunity to
find novel proteins and other biomolecules that are not necessarily associated with the amyloid
and tau proteins. The disadvantage is the number of false positives that may arise due to the
natural range of concentration for a protein, typically small numbers of specimens assayed and
sampling bias (Lista, Faltraco et al. 2013). I have used the second method, described here, to find
novel biomarkers.

1.4.3 Electrospray Ionization-Quadrupole-Time-Of-Flight Mass Spectrometer: Most
Frequently Used Instrument for Biomarker Discovery
Mass analyzers such as quadrupole, time of flight, ion trap, or fourier transform ion cyclotron
resonance and recently orbitrap instruments are used for biological mass spectrometry based
biomarker discovery research. Mass spectrometry has become the preferred tool for biomarker
discovery due to its increased resolution, sensitivity, high mass accuracy, and rapid tandem MS
abilities, allowing for the identification of many biomarkers of interest (Alvarez 2013). I used

28

electrospray ionization (ESI) interfaced with quadrupole–time-of-flight (QqTOF) instrument for
my experiments. It is described in the following sections.
William Stephens of the University of Pennsylvania first put forward the idea of a time-offlight mass spectrometer, which was constructed in the late 1940s. In the mid 1950s, Wolfgang
Paul of the University of Bonn detailed the concept of the quadrupole mass spectrometer (Paul
and Steinwedel 1953). The quadrupole mass filter and time-of-flight mass analyzer were later
coupled and the first commercial QqTOF was launched in 1996. The technique of QqTOF was
modeled closely after the electrospray ionization time-of-flight (ESI-TOF) system
(Chernushevich, Loboda et al. 2001). The tandem instrument provides for ion fragmentation with
the second detector measuring the daughter ions and allowing for amino acid sequencing.
Electrospray ionization is a soft ionization technique and is required to interface liquid
chromatography systems with a tandem mass spectrometer set-up that involves converting liquid
phase samples into gas phase ions.
The normal components of QqTOF instrument are a continuous ion source, ion
transmitter/mass filter, ion optics, an ion modulator, a drift region, an ion reflectron mirror, a
detector and data recording electronics. The ion source can be ESI, atmospheric pressure
ionization, etc. and consist of a filtered stream of ions having mass-to-charge ratios in a specific
range to which the quadrupole is tuned (Chernushevich, Ens et al. 1999). The ion transmitter or
mass filter in such an instrument is a quadrupole. The ion modulator, drift region and ion
refectron mirror generally constitute the TOF analyzer. A schematic diagram of a QTOF
instrument is shown in Figure 1.6.
As can be seen, ions pass through three quadrupoles (Q0, Q1 and Q2). Q0 and Q2 are
radiofrequency (rf) only quadrupoles that act as collision dampeners for the beam coming in
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the strengths and the limitations of the technique (perhaps
debunking some common perceptions while supporting others), the advantages provided by the ion sources that are most
widely used
and the power of instrument control and data
	
  
processing software. It should be noted that the last aspect is
a moving target; it is likely that by the time this paper is read,
new automation capabilities will have been developed and
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through the ion source. This is required to narrow the spatial and velocity spreads of the beam
resulting from the velocity distribution of the ions in the direction of injection. The r.f. field in
the quadrupole acts as a potential well, which allows the ion beam to be radially constricted. For
single MS operation, Q1 acts in the r.f.-only mode, i.e., as a transmitter, whereas for the MS/MS
mode, Q1 acts as a mass filter, allowing only ions within a specific range of m/z to pass through
to the analyzer. Q1 then accelerates the ions towards Q2 where the ion beam collides with the
neutral gas molecules, such as argon undergoing collision-induced dissociation (Faria, Gonçalves
et al. 2014) to generate fragment ions. These ions are again focused through the collision
dampening process described above into the TOF analyzer (Chernushevich, Ens et al. 1999,
Chernushevich, Loboda et al. 2001).
The focused beam is now passed to the ion modulator inside the TOF analyzer perpendicular
to the z axis. This is called orthogonal modulation. The theory behind orthogonal injection stems
from the fact that it is hard to feed a continuous beam of ions to the TOF analyzer. A simple but
ineffective way is to open the gate at regular intervals and let ions through; however this
drastically affects the throughput. Since TOF analyzers can tolerate larger spatial spread of ions,
the ions can be fed parallel to the electrodes rather than through the electrodes. This is the most
efficient way of injecting ions into the TOF without affecting throughput. Once the ions are in
the TOF analyzer, they are repelled and accelerated by the electrodes into the field-free drift
region and eventually into the reflector where the ions become reflected on to the detector. The
extra shield is required for the inverted configuration to generate the field-free drift region in the
TOF section. The mass spectra are measured using a time-to-digital converter (TDC)
(Chernushevich, Ens et al. 1999, Chernushevich, Loboda et al. 2001).
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1.4.3.1 Electrospray Ionization
Analysis of large biological molecules in mass spectrometry requires conversion of the
molecules into gas-phase ions, which was not possible to achieve with conventional methods of
ionization such as electron ionization, photon ionization and chemical ionization without
significant pyrolysis and decomposition. That explains the focus over the last 45 years on
developing soft ionization methods to ionize large molecules. One category of such methods is
based on the working theory that when adequate energy is unleashed rapidly over the molecules,
it will bring about evaporation before decomposition (Beuhler, Flanigan et al. 1974). The source
of energy can differ based on the methods used. For example, in plasma desorption (PD), the
molecules are bombarded with a radioactive isotope, usually californium-252. Fast ion
bombardment (FIB) makes use of a beam of high-energy ions. Laser desorption (LD) makes use
of photons as the source of energy. These methods are highly effective in extracting intact
molecular ions from large molecules (Fenn, Mann et al. 1989).
The other category of ionization methods involves use of powerful electrostatic fields to
obtain ions from molecules. Field desorption (FD) is an example of such a method where the
molecules are applied to a fine wire covered with an array of sharp pointed needles that generate
the strong electric field. Electrohydrodynamic ionization (EH) is another example that involves
dissolution of the sample in a non-volatile, low vapor pressure liquid (like glycerol) passed into a
high voltage chamber through a capillary tube. These methods have some commercial
constraints such as costly magnetic sector analyzers, tiresome sample preparation processes,
unavailability of low vapor pressure liquids, etc. (Fenn, Mann et al. 1989).
A more recent category of spray ionization techniques also involves use of electric fields to
extract ions. The difference is that ambient bath gas is used instead of vacuum. There are three
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methods currently, which use this technique: aerospray ionization (ASI), thermospray ionization
(TSI) and ESI.
I used ESI to be able to observe multiply charged peptides of MW of ≤10000 D. In ESI, the
sample is continuously passed through a stainless steel or a quartz silica hypodermic needle that
is maintained at a high voltage (2.5-6 kV) relative to the chamber around it. Because of the
electric field generated around the tip of the needle, the surface of the liquid becomes charged
with the same polarity as that of the needle and becomes dispersed into a very fine spray of
charged droplets by Coulombic forces that move towards the end wall of the chamber. A
concurrent flow of a high flowrate bath gas (such as nitrogen) in the chamber maintained at high
temperature expedites the evaporation of the solvent from the droplets, thereby decreasing their
radii progressively. Consequently, the charge density of the surface keeps on increasing until it
reaches the Rayleigh limit at which the Coulombic repulsion is equivalent to that of the surface
tension that eventually explodes the droplet apart, producing even smaller droplets. This cyclic
process keeps repeating until the radius of the droplet becomes small enough to allow the surface
charge density to be strong enough to extract the ions from the droplet and pass them into the
ambient gas (Fenn, Mann et al. 1989, Ho, Lam et al. 2003). This explains ion evaporation model.
According to the charge residue model the electrospray droplets undergo evaporation and fission
cycles, subsequently forming smaller droplets containing on an average one one analyte ion.
The emitted ions are swept along with the flow of the bath gas into the glass capillary tube
and emerge out of it as a free flowing jet of ions. These are then sampled through a skimmer
cone and then passed on to the entrance of a mass spectrometer, such as a quadrupole TOF. The
entire setup is shown in Figure 1.7.
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Figure 1.7. Electrospray ionization setup. Reprinted from (Fenn, Mann et al. 1989) with permission.
©American Association for the Advancement of Science, 1989.
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1.4.3.2 Quadrupole as Mass Filter
The quadrupole mass analyzer filters specific mass ions by applying an AC and DC potential
on the electrodes. The effect of the potentials on the ions is the basis of the mass filtering
property of the analyzer. Let me first take the effect of the AC potential on the ions traversing the
X-Z plane in the absence of the DC potential. In this scenario, the electrodes spend half the cycle
at a positive potential and half the cycle at a negative potential. In the positive cycle, the ions are
pushed towards the central axis of the electrode structure, whereas in the negative cycle, the ions
are pulled towards the negatively charged electrodes (Figure 1.8). The collision of these ions
with the electrodes is dependent on the negative cycle duration, the magnitude of the negative
cycle and the position, speed and mass/charge (m/e) ratio of the ion.
Next, let’s consider the case where a positive DC potential is applied to the electrodes on the
X-axis along with an alternating AC potential of high frequency. Because of the high frequency
of the AC voltage, the only ions that will be affected by the AC and DC voltage will be ions with
low mass. Ions with heavy masses won’t ‘feel’ the negative effect of the AC voltage to a large
extent since the frequency of oscillation between cycles is high. So, the amount of time the ions
will be affected by the negative cycle of the AC voltage will be very low. Thus, the heavier ions
tend to be affected more by the positive DC potential that pushes them towards the central Z-axis.
In summary, ions with heavy masses tend to pass through, in this case, making the quadrupole a
high-pass filter. The graph below [Figure 1.9 (a)] shows this behavior.
The potentials on the Y-Z plane will be opposite compared to those on the X-Z plane. That’s
why there will be a negative DC potential along the Y-Z plane, and the AC potential will be 180
degrees out of phase compared to the X-Z plane. If the frequency of oscillations of the AC
voltage is high, the only ions that will stay near the central axis will be ions with low mass, since
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Figure 1.8. Operation of a quadrupole in the X-Z and Y-Z plane. Reprinted from (Ginsbach and
Dunnivant 2008) with permission. ©American Chemical Society, 2008.
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they will be repelled by the positive cycle of the AC potential. All other ions with heavier mass
would be attracted towards the negatively charged DC potential. Therefore, ions with low mass
would be those that would pass through the quadrupole, making it function as a low-pass filter in
this case as seen in Figure 1.9 (b).
Because of the alternating behaviors of ions on the X-Z and Y-Z planes, the quadrupole acts
as a band-pass filter where only ions with a certain mass are allowed to pass through. Thus,
adjusting the AC and DC potentials can vary this band of m/z and allow ions only within a
specific range to pass by (Miller and Denton 1986). The graph Figure 1.9 (c) combines the two
graphs [Figure 1.9 (a) and 1.9 (b)] to show the band of masses that are allowed to pass.

1.4.3.3 Time-of-Flight Mass Spectrometer
A time-of-flight mass spectrometer consists of an electrode at a certain voltage and a
grounded electrode separated by a certain distance. The ions, which come into the instrument get
repelled by the higher potential electrode towards the grounded electrode thereby gaining
velocity. The grounded electrode is basically a mesh, which is used to pass these ions through in
a drift free region where they travel with constant velocity till they reach the detector. Based on
the equations in the Appendix, the time required for an ion to reach the detector is directly
proportional to the square root of its mass. This leads to ions of the same mass reaching the
detector at the same time thereby differentiating them in the mass spectrum. This is the
fundamental working principle of the time of flight mass spectrometer.
The resolution of the mass spectrometer decreases with increase in the mass of ions because
of the square root factor. Since ions are not created at a unique point between the electrodes
because of the width of the electron beam creating them, for any charge to mass ratio, there will
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Figure 1.9. Quadrupole as a band pass filter. Reprinted from (Ginsbach and Dunnivant 2008) with
permission. ©American Chemical Society, 2008.
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be a range of flight times which will make the mass peaks overlap each other and blur the
spectrum, especially for high masses. Currently, there are two techniques to deal with this
problem. The first is space focusing. The concept for this goes back to the fact that ions created
near the repeller electrode will receive larger acceleration than ions created farther away. By
adding an extra electrode for additional acceleration of the ions and choosing the distances and
voltages with precision, it can be assured that ions with the same mass-to-charge ratio will reach
the detector at the same time, thereby improving the resolution (Figure 1.10).
The second technique is time lag focusing. Molecules move at different speeds in a gas
according to the Maxwell-Boltzmann velocity distribution. This leads to ions having varying
initial velocities between the time they are created and the time they receive the acceleration
from the electrodes. This also leads to blurring of the flight times, which affects the resolution.
To compensate for that, a time lag can be introduced to nullify the spread of the initial
velocities of the gas molecules. The current way of achieving this effect is the use of a reflectron.
A reflectron is basically a panel of electrodes with varying voltages having a constant potential
difference between them starting from 0 V (ground). When ions with the same masses but
varying velocities are directed towards the reflectron, they are repelled. However, ions having
higher velocities go deeper into the reflectron before being repelled compared to the ions having
lower velocities. The net result of this is that ions entering the reflectron with varying velocities
will come out of it with similar velocities and reach the detector at the same time, thereby
improving the resolution and making the mass peaks more distinct (Gross 2004, Whitaker 2012).
The detector is an electron multiplier that amplifies the charge falling on it and converts it into a
voltage signal, which is fed to an oscilloscope to generate a mass spectrum.
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Figure 1.10. TOFMS with two electrodes for space focusing. Reprinted from (Yildirim, Sise et al.
2010) with permission. ©Elsevier, 2010.
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1.5 Layout of the Dissertation
Chapters 2, 4, and 5 are different parts of the initial serum AD biomarker discovery study.
Chapter 3 is a validation study that focused on validating the few most promising biomarkers
that looked diagnostically different from the study described in Chapter 2. Chapter 3 also lays the
foundation for future research. Chapter 6 concludes the dissertation by discussing potential
pitfalls and future research.
Chapter 2 details work on the initial discovery of novel serum AD biomarkers. Chapter 3
describes the results of a study designed to validate the diagnostic biomarkers that are discussed
in Chapter 2, particularly those that were found repeatedly in multi-marker panels. This chapter
also details identification of the biomarkers. Chapter 4 describes the findings of novel
biomarkers when genders were studied separately. Chapter 5 compares different stages of AD
and describes attempts to find novel biomarkers that might be predictive of different stages,
specifically earlier stage AD. Detailed equations of quadrupole and time of flight mass
spectrometer are included in the appendix.
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CHAPTER 2 – INITIAL STUDY OF NOVEL SERUM BIOMARKERS FOR
ALZHEIMER’S DISEASE

2.1 Abstract
Background: Deaths from AD increased by 68% in the first decade of the 21st century, while
deaths from all other major diseases declined. This emphasizes the continued need for useful
treatments, which in turn necessitates accurate serum biomarkers for AD. To address this need,
we used an innovative serum proteomic approach to examine the low-molecular weight
components in serum to find prospective biomarkers.
Methods: Serum samples from 58 cases with any clinical stage of AD and 55 matched
controls from non-demented individuals were processed to deplete high abundance proteins. The
processed samples were fractionated on a reversed phase capillary column and analyzed using an
ESI-QTOF mass spectrometer (MS). Approximately 8000 MS features were observed. Data for
species that appeared quantitatively different between case and control were evaluated
statistically. Furthermore, using logistic regression analysis and a leave-one-out approach,
combinations of statistically different or near different biomarkers were evaluated to determine if
they provided improved diagnostic capability.
Results: We found 38 biomarkers with significant differences between cases and controls.
Multi-marker panels were built that resulted in specificities and sensitivities greater than 80%.
Conclusion: The serum proteomics approach was successfully used to find serum biomarkers
for AD.
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2.2 Introduction
The rate of new Alzheimer’s disease (AD) continues to grow as the average length of life of
the population increases (Association 2013). Likewise, the dramatic increase in diabetes appears
to have added to the number of individuals developing AD. Currently, there are no treatment
options for AD. The absence of medications that attenuate AD reflects the current inability to
identify unambiguously those who have the disease and the unavailability of serous or radiologic
changes that identify very early AD when an intervention could slow or interrupt disease
progression. Drug studies in sporadic AD are not currently possible due to the lack of good
diagnostic tests for earlier stage AD.
Clearly, having accurate and easily applied biomarkers specific for AD, especially early AD,
is critical for developing pharmacologic interventions in AD and would be useful in clinical
management of AD thereafter. Not surprisingly, there have been many attempts to find
diagnostic biomarkers for AD over the years. Out of these several studies, there are a few
cerebrospinal fluid (CSF) biomarkers that appear to have the most potential. Reduced levels of
amyloid beta protein 1-42 (Aβ-42) and increased levels of microtubule associated protein tau (ttau and phosphorylated tau) in the cerebrospinal fluid are frequently found in severe cases of AD
patients and are believed to indicate the presence of significantly progressed disease and
potentially earlier, developing disease. However, CSF levels of these two peptides have been
found to be almost the same in patients with mild cognitive impairment compared with controls,
thereby making use of these biomarkers very limited for early diagnosis of AD. Even though
improvements have been made in the recent past to increase the sensitivities of these assays,
there is still the drawback of actually getting CSF samples from the very large affected or at risk
population. Getting cerebrospinal fluid for a test is invasive, slow and expensive and, hence, not
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practical for testing the very large, aging population. All of these reasons support the need for
finding biomarkers in blood (Selkoe 2000, Sunderland, Linker et al. 2003, Blennow 2004,
Hansson, Zetterberg et al. 2006, Hu, Hosseini et al. 2007, Ringman, Coppola et al. 2012).
There is currently some evidence that the blood-brain barrier of AD patients is damaged,
allowing Aβ to cross the barrier and enter the peripheral blood circulation. This may lead to
changes in the presence or quantity of the proteins, peptides and other molecules in the blood,
eventually opening the door to finding biomarkers to diagnose AD (Deane and Zlokovic 2007,
Zipser, Johanson et al. 2007, Lue, Walker et al. 2009). The preponderance of blood-based
biomarker research has focused on for Aβ-42, tau, and P-tau. However, the research shows major
inconsistencies when these CSF markers are studied in blood. Studies have found an unusual
expression pattern of amyloid-β protein precursor isoforms found in AD platelets, and altered
gene expression profiles in AD lymphocytes, but these have not resulted in functional
biomarkers (Mueller, Zhou et al. 2010, Watt, Perez et al. 2011).
In contrast to this, a very different approach to finding biomarkers has been gaining
popularity. In this strategy, all the proteins that show up in a mass spectrum are considered and
evaluated to find biomolecules in plasma or serum whose quantities differ between cases and
controls (Zürbig and Jahn 2012, Ghidoni, Paterlini et al. 2013, Lista, Faltraco et al. 2013).
Specifically, the approach involves sampling serum from symptomatic AD candidates and nondemented controls and performing two dimensional gel electrophoresis (2DGE) on the samples
for differential comparison (Zhang, Barker et al. 2004, Lopez, Mikulskis et al. 2005, Hye,
Lynham et al. 2006, Liu, Hu et al. 2006, German, Gurnani et al. 2007, Liao, Yu et al. 2007,
Akuffo, Davis et al. 2008, Cutler, Akuffo et al. 2008, Thambisetty, Simmons et al. 2010, Henkel,
Müller et al. 2012). The molecules that appear different between the cases and controls are then
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removed and digested using trypsin and evaluated by MALDI-MS to identify the putative parent
proteins. Most of the studies implementing this approach follow the identification process above
with a second verification step where immunoassays are developed to the relevant proteins and
are used to quantitate the proteins as part of a second study. This proteomic approach has some
strong points, but it comes with a number of drawbacks (Henkel, Müller et al. 2012).
First, the insensitivity of the electrophoretic gel methods makes it difficult to reproduce the
same results on a consistent basis (Zhang, Annan et al. 2010, Henkel, Müller et al. 2012). The
current 2D-GE methods only allow abundant proteins to be measured. A study by Hye et al.
found 15 different protein peaks that were AD diagnosis candidates, out of which 13 were
components of immunoglobulin or serum albumin precursor (Hye, Lynham et al. 2006). Second,
multiple peaks in 2D gels may point to the same protein that is changed by different posttranslational modifications such as glycosylation or glycation. The low resolution of 2D gels
makes it harder to comparatively and quantitatively differentiate one protein from the other. This
is due to presence of multiple molecules in the same spot. Third, the non-specific stains (that
often display increased intensity with an increase in the size of the protein) used in gel
electrophoresis, like Coomassie blue, makes this method much less sensitive to smaller proteins
and peptides that could include signaling and regulatory proteins. Fourth, posttranslational
modifications could result in one pool of proteins having the same expression levels as another
pool even when they appear different in quantity and vice versa. This is when two pools
represent the same protein with different modifications. Finally, several of these studies use a
single pooled specimen for cases and a single pooled specimen for controls. The ability to
evaluate the uniformity of the observed change is often lost when the specimens are pooled
together for experiments.
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The research of blood biomarkers of AD using electrophoretic gel methods (2D-GE) until
now has yielded ambiguous results with inconsistent markers (Lopez, Mikulskis et al. 2005, Hye,
Lynham et al. 2006, Liu, Hu et al. 2006, German, Gurnani et al. 2007, Liao, Yu et al. 2007,
Akuffo, Davis et al. 2008, Cutler, Akuffo et al. 2008, Thambisetty, Simmons et al. 2010, Henkel,
Müller et al. 2012). Furthermore, with few exceptions, immunoassay studies on the biomarkers
identified in the discovery phase have not found any quantitative difference between cases and
controls in the validation phase. These results should not be interpreted as an absence of blood
AD biomarkers, but rather a reflection of the insensitivity, non-specificity and poor
reproducibility of 2D-GE protein observation and quantitation methods. More thorough reviews
of current blood proteomic studies have been published (Zürbig and Jahn 2012, Ghidoni,
Paterlini et al. 2013, Lista, Faltraco et al. 2013).
Alternative techniques have been tried to find new biomarkers for AD. Ray et al. used
antibody arrays to evaluate plasma levels of 120 cell-signaling proteins in cases versus controls
and found a combination of 18 proteins which diagnosed AD with 90% accuracy (Ray, Britschgi
et al. 2007). Another approach was implemented by Reddy et al. who investigated a
combinatorial library of immunoglobulins against serum to discover IgG molecules unique to
AD (Reddy, Wilson et al. 2011). Some studies have focused on higher plasma levels of oxidized
proteins or glycoproteins (Choi, Malakowsky et al. 2002, Yu, Chertkow et al. 2003), while other
studies have not been able to reproduce the same results (Lista, Faltraco et al. 2013).
Newer proteomic methods have not been used to discover AD serum biomarkers. MUDPIT,
a shotgun or global proteomics approach, is regularly used to investigate the set of proteins in a
tissue or cell (Vaudel, Sickmann et al. 2012). However, present applications of MUDPIT don’t
allow quantitative comparisons. My study makes use of an approach that focuses on the low
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molecular weight components in serum by initially depleting high abundance proteins and then
performing capillary liquid chromatography coupled to tandem mass spectrometry to study
molecules in serum (Merrell, Southwick et al. 2004, Merrell 2009, Esplin, Merrell et al. 2011).
This approach interrogates around 8000 spectral features (Alvarez, Shah et al. 2013) and has
been applied successfully to proteomic biomarker discovery in other clinical indications (Esplin,
Merrell et al. 2011).
I propose that this proteomics approach will identify biomarkers for AD in serum. This
method, combined with biostatistical analysis should provide panels of serum biomarkers that
effectively diagnosis AD.

2.3 Materials and Methods

2.3.1 Sample Collection and Study Population
Serum specimens were procured from the Knight Alzheimer’s Disease Research Center
(ADRC) at the Washington University School of Medicine, St. Louis, MO (WUSTL). Formerly
collected serum specimens from cases (n=58) and controls (n=55) were provided. The cases
represented AD patients with different clinical dementia ratings (CDR), particularly: mild
cognitive impairment or very mild AD (CDR= 0.5, n=7), mild AD (CDR= 1.0, n=4), moderate
AD (CDR= 2.0 n=19) and severe AD (CDR= 3.0 n=28). The 58 cases and 55 controls did not
have co-morbidities, including diabetes. All specimens were stored at −80 °C prior to processing
and analysis.
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2.3.2 Ethics Statement
Approval from Washington University Institutional Review Board (IRB) was in place at
Knight ADRC, WUSTL, prior to the original studies being conducted, and IRB approval was
likewise obtained at Washington University School of Medicine, Knight ADRC prior to the
current specimens being provided to BYU for these studies. All participants signed a written
informed consent form when the samples were originally collected, which also provided
permission to use the sera for later laboratory research. Specimens were provided without any
personal identifiers. Furthermore, the laboratory studies at BYU involving these specimens had
approval from the Institutional Review Board for Human Subjects at BYU.

2.3.3 Sample Processing
Serum contains many highly abundant proteins like albumin. Highly abundant proteins lead to
ion suppression of low abundance biomolecules when analyzed by MS. Hence, in the novel
approach used here, these larger proteins were removed using an acetonitrile precipitation
protocol (Merrell, Thulin et al. 2008, Merrell 2009, Alvarez, Shah et al. 2013). This substantially
increases the number of biomolecules observable by MS. It also displaces many small molecules,
particularly peptides, from large carrier proteins. Sera to be studied were thawed on ice, mixed
and 200 µL aliquoted. To this, 400 µL of HPLC grade acetonitrile was added immediately,
vortexed for 20 s and allowed to sit at room temperature for 30 min. Post centrifugation (10,000
rpm), the supernatant (~550 μL) was transferred to a clean tube and 300 μL of HPLC grade water
was added. The samples were then evaporated to ~200 μL (the original volume of the aliquot) in
a vacuum centrifuge (Labconco CentriVap Concentrator, Labconco Corporation, Kansas City,
MO). This step helps remove the final traces of acetonitrile to prevent inconsistencies during LC
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separation. Apparent protein concentration was determined by Bio-Rad microliter plate protein
assay performed according to the manufacturer's instructions (Bio-Rad Laboratories, Hercules,
CA). An aliquot containing an apparent protein concentration of 2 μg was transferred to a new
microcentrifuge tube and brought down to <10 μL in the vacuum centrifuge. Samples were
brought up to 10 μL with HPLC water and acidified with addition of 10 μL 88% formic acid
(FA).

2.3.4 Analysis of Sera on a Capillary-LC-ESI-QTOF Mass Spectrometry System
The protein-depleted, acidified sample was loaded onto a capillary liquid chromatography
(cLC) system capable of gradient elution to separate compounds according to their polarities
prior to the column being interfaced with a tandem mass spectrometer. I randomized the samples
to keep bias to a minimum and ran sample sets in as short a time as possible. The pump used was
an LC Packings Ultimate Capillary HPLC pump system, with a FAMOS autosampler (Dionex
Corporation, Sunnyvale, CA) maintained at 4°C. The quaternary pump delivers two different
solutions: an aqueous solution (98% HPLC grade H2O, 2% acetonitrile (ACN) and 0.1% FA) and
an organic solution (2% H2O, 98% ACN and 0.1% FA) at a specified composition via a mixing
device situated prior to the pump. This helps in achieving more consistent chromatographic
separation. A 1 mm (16.2 µL) microbore guard column from Upchurch Scientific, Oak Harbor,
WA, and a 15 cm x 250 µm i.d. capillary column made in-house were utilized for
chromatographic separation. While the capillary column was slurry packed; the guard column
was dry-packed. Both columns used POROS R1 reversed-phase media from Applied
Biosystems, Framingham, MA. Sample was introduced and retained on the guard column and
then eluted from the capillary column using the following gradient: 3 min of 95% aqueous and
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5% organic phase, followed by a linear rise in organic phase to 60% over the next 24 min.
Thereafter, the solvent mix was increased linearly to 95% organic phase and 5% aqueous phase
over the next 7 min, then held at 95% organic phase for 7 min and returned to 95% aqueous
phase over 5 min. The column was allowed to re-equilibrate until the end time of the run (58
min). The flow rate used is 5.0 µL/min.
The cLC system was interfaced via an IonSpray source from Applied Biosystems to a
QSTAR Pulsar I quadrupole/orthogonal time-of-flight mass spectrometer set at 4800 V. MS data
were collected for m/z range of 500 to 2500 starting at 5 min and ending at 55 min of gradient
elution. The positive ion mode was used with a scan rate of 1 spectrum/s. The Analyst QS®
software package permitted effective data collection, preliminary formatting, MS spectral
comparison, extraction of selected-ion chromatograms and analysis.

2.3.5 Time Normalization of the MS Data
There is a slight inherent variability in chromatographic elution times from one sample to
another. A set of 10 endogenous molecular species, consistently present in all specimens, was
selected as internal standards. The compounds in the series elute at approximately two-minute
intervals from each another. This allowed for the same time windows to be considered for each
specimen run. Data were organized in two-minute windows centroided on each marker or where
there were gaps between two time markers. The time markers allowed for time normalization,
providing uniformity in chromatographic elution windows over the important chromatographic
region (~15 to ~35 min) as described in detail by Merrell et al. (Merrell, Thulin et al. 2008).
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2.3.6 Selecting Candidate Biomarkers
MS spectra were compiled from 1 min before to 1 min after each endogenous time marker
for each sample to generate a composite spectrum. In turn, spectra from AD cases and normal
controls were color coded and overlaid to allow for direct analysis of each individual molecular
species. Peaks that appeared quantitatively different between cases and controls were then
quantitated by extracting the ion counts of the desired peak, specifying an m/z range to capture
the peak envelope using the “XIC” function of the MS instrument software for each of the
samples. The peak heights were then recorded for all samples in an Excel file for each of the
potential AD biomarkers (Merrell, Thulin et al. 2008). The extracted data were then tested using
the Student’s t-test to determine if they were statistically different. A p-value < 0.05 was
considered statistically different.

2.3.7 Normalization of the Candidate Biomarkers
Non-biological variability can arise from several sources as part of proteomic studies. These
include variability in specimen processing, specimen stability, ionization efficiency, and
instrument sensitivity among others. To reduce variability, a previously tested approach was used.
To accomplish this, a set of naturally present serum molecules was selected as internal references.
The ideal reference was present in the same time window, had a similar m/z value, was
consistently there, was well separated from other peaks, was easily measured and was
quantitatively comparable between cases and controls. Each of these was then used to normalize
a potential biomarker to compensate for the non-biologic variability between samples. The peak
intensity of a candidate biomarker species was ratioed to the intensity of a co-eluting species.
Normalization with the use of this endogenous control typically improved the statistical
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difference between cases and controls for candidate peaks. Unnormalized raw and log
normalized values were calculated for each of the potential biomarker candidates and retested
statistically. Again, a p-value <0.05 was used to define candidate serum biomarkers.

2.3.8 Biostatistical Analysis
In addition to the Student’s t-test that was applied to the initial data screen, other statistical
tests were carried out. Logistic regression analysis was used to generate receiver operator
characteristic curves for each of the candidate biomarkers to find their sensitivities and
specificities. Sensitivity is defined as the fraction of cases correctly identified by a given
biomarker. Specificity reflects the fraction of controls correctly defined by a given biomarker.
Then, sets of candidate markers were modeled to obtain a combination that provided better
diagnostic discrimination. A p-value <0.05 was considered significant but all biomarker
candidates with p-values less than 0.10 were considered since there is likelihood that some of
these may be complementary to other candidate biomarkers even if they themselves do not
satisfy criteria for statistical significance. Logistic regression analysis was also used to evaluate
combinations of biomarkers to model the log-odds of developing AD. Correlation analysis
helped in studying the biomarker clusters. The biomarkers in the same subgroup within the
cluster provided similar discrimination between cases and controls, and may represent
components from the same parent compound or represent a common response or pathway, while
those that appeared to segregate provide complementary diagnostic information and may
represent differences in staging of disease or in the involvement of potential pathways. Finally, a
forward-selection statistical procedure was used. In this approach, the candidate markers were
added to the model one at a time, beginning with each individual marker. The inclusion of other
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markers on a one by one basis was tested to see if the combination of the markers increased the
area under the receiver operator characteristic curve (AUC, a measure of overall diagnostic
utility) by at least 0.03. In this way it was possible to obtain combinations of biomarkers giving
the highest possible AUCs. This defines the ‘leave-one out’ prediction approach. Several
potentially useful panels of AD biomarkers were obtained this way. ROC curves were plotted
once again to study the combined sensitivities and specificities of these multi-marker models.

2.4 Results

2.4.1 Evaluating Potential Batch Effects
Notwithstanding that a mixed set of samples representing cases and controls were run every
day until they were all finished, there were batches of specimens run on different days. This can
sometimes lead to bias. However, when a hierarchical clustering algorithm was applied to the
data, no clusters or observable patterns associated with run date were observed.

2.4.2 Candidate Serum AD Diagnostic Biomarkers
When studying raw and un-normalized mass spectral data, we found 44 candidate serum AD
biomarkers that were statistically significant in the all-stage AD set (CDR = 0.5, 1.0, 2.0, 3.0)
compared with the matched, non-demented control set (CDR = 0). There were additionally 25
biomarkers that had p-values between 0.05 and 0.10. With log normalizing the data for each
candidate to an endogenous molecular reference species (that was equivalently distributed
between cases and controls), there remained 38 significantly different serum biomarkers and 21
candidates that were near significant (p = 0.05 to < 0.10). Many of these were significantly
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Table 2.1. Biomarkers considered for biostatistical analysis with significant (< 0.05) or near
significant (< 0.1) p values.
p value for
log of ratio
of potential
biomarker
to reference
biomarker

p value for
unnormalized
potential
biomarker

p value for
unnormalized
ref. biomarker

Candidate
number

Elution
time
window
(min)

m/z of
biomarker

Charge
(Positive
ion mode)

p value for
ratio of
potential
biomarker
to reference
biomarker

1

8-15

921.4

1

0.0494

0.035

0.0214

0.4524

2

8-15

1091.4

1

0.0857

0.0192

0.0538

0.4472

3

8-15

752.3

2

0.1565

0.1189

0.0878

0.3806

4

11-15

531.3

1

0.0449

0.0414

0.0635

0.487

5

11-15

515.3

1

0.1249

0.0482

0.0052

0.487

6

11-15

1107.5

1

0.0731

0.0218

0.1535

0.487

7

11-15

561.2

1

0.0866

0.1615

0.2144

0.487

8

11-15

574.3

1

0.0778

0.3269

0.3238

0.487

9

11-15

597.8

2

0.386

0.3673

0.0703

0.487

10

11-15

602.3

1

0.0905

0.0787

0.1492

0.487

11

11-15

690.8

2

0.072

0.3121

0.3938

0.487

12

11-15

701.8

2

0.0865

0.0946

0.0684

0.487

13

11-15

708.3

1

0.0812

0.2063

0.0762

0.487

14

11-15

821.3

1

0.0606

0.045

0.1389

0.487

15

11-15

892.4

1

0.1487

0.217

0.0392

0.487

16

11-15

971.4

1

0.0836

0.0986

0.2517

0.487

17

11-15

1194.5

1

0.1015

0.0854

0.1503

0.487

18

11-17

1396.6

1

0.0506

0.0919

0.1442

0.2468

19

13-19

587.3

1

0.0918

0.014

0.0785

0.2468

20

13-19

989.3

4

0.0952

0.1129

0.094

0.4886

21

13-19

791.6

5

0.1144

0.1405

0.0837

0.4886

22

16-22

748.6

1

0.1808

0.1143

0.0309

0.3663

23

16-22

704.5

1

0.0831

0.04

0.0149

0.3663

24

16-22

778.6

1

0.0416

0.0214

0.0136

0.3663

25

16-22

583.3

1

0.0115

0.0379

0.0002

0.3663

26

16-22

660.5

1

0.1229

0.0533

0.0258

0.3663
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27

16-22

734.5

1

0.0678

0.0278

0.0157

0.3663

28

16-22

924.6

1

0.2164

0.1387

0.0822

0.3663

29

16-22

880.6

1

0.1696

0.0729

0.0569

0.3663

30

16-22

822.5

1

0.1146

0.0584

0.0312

0.3663

31

16-22

819.5

1

0.1701

0.2171

0.0813

0.3663

32

16-22

616.4

1

0.1363

0.0652

0.0177

0.3663

33

16-22

626.4

1

0.0534

0.1264

0.0703

0.3663

34

17-25

502.3

1

0.1083

0.1636

0.0028

0.147

35

17-25

512.4

1

0.2105

0.1737

0.0297

0.147

36

17-25

518.3

1

0.2331

0.2397

0.0516

0.147

37

17-25

520.3

1

0.375

0.4531

0.029

0.3837

38

17-25

542.4

1

0.1347

0.0975

0.0051

0.147

39

17-25

560.4

1

0.0263

0.0219

0.055

0.147

40

17-25

564.3

1

0.0845

0.0226

0.001

0.147

41

17-25

614.4

1

0.1679

0.0674

0.1048

0.147

42

17-25

629.4

1

0.2842

0.1131

0.0428

0.3837

43

17-25

687.4

2

0.148

0.0203

0.0614

0.147

44

17-25

701.5

1

0.2589

0.0862

0.0211

0.3837

45

17-25

804.6

1

0.055

0.0188

0.0555

0.1461

46

17-25

861.6

1

0.3184

0.1943

0.043

0.3837

47

17-25

938.7

1

0.0838

0.0464

0.0385

0.147

48

17-25

1021.7

1

0.3016

0.4593

0.0808

0.147

49

17-25

1126.8

1

0.0313

0.0148

0.0215

0.147

50

17-25

1156.9

1

0.108

0.0663

0.1175

0.147

51

17-25

1170.9

1

0.044

0.0212

0.0332

0.147

52

20-27

544.3

1

0.3909

0.3928

0.0085

0.4623

53

22-32

513.3

1

0.0079

0.0163

0.0228

0.1225

54

22-32

660.4

1

0.0186

0.0113

0.0579

0.0984

55

22-32

568.4

1

0.4693

0.4398

0.0347

0.1243

56

25-34

530.4

1

0.0201

0.0183

0.2205

0.4059

57

25-34

790.6

1

0.0636

0.0506

0.0872

0.4059

58

25-34

830.6

1

0.0558

0.013

0.047

0.4059

59

25-34

848.6

1

0.03

0.0048

0.014

0.4059
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60

25-34

856.6

1

0.0155

0.0034

0.0162

0.4059

61

25-34

878.6

1

0.0424

0.0085

0.0243

0.4059

62

25-34

535.4

1

0.0869

0.1409

0.2034

0.4059

63

25-34

653.4

1

0.0973

0.1098

0.1767

0.4059

64

25-34

804.6

1

0.1639

0.0822

0.1522

0.4059

65

29-37

1540.2

1

0.0278

0.027

0.002

0.4417

66

29-37

744.6

1

0.2436

0.2068

0.0332

0.448

67

29-37

730.6

1

0.1185

0.0971

0.087

0.448

68

29-37

874.6

1

0.1235

0.0044

0.0133

0.448

69

29-37

758.6

1

0.2079

0.2869

0.0152

0.448

70

29-37

1516.2

1

0.017

0.016

0.0223

0.448

71

31-38

808.6

1

0.0075

0.0057

0.0002

0.1961

72

31-38

675.6

1

0.1845

0.0713

0.0912

0.1961

73

31-38

784.6

1

0.0466

0.0409

0.0886

0.1961

74

31-38

1618.2

1

0.0086

0.0119

0.0161

0.1961

75

31-38

1592.2

1

0.0093

0.01

0.014

0.1961

76

31-38

810.6

1

0.0044

0.0049

0.0022

0.1961

77

31-38

834.6

1

0.0384

0.0402

0.0616

0.1961

78

31-38

1568.2

1

0.0018

0.002

0.0014

0.1961

79

31-38

1576.2

1

0.0214

0.0089

0.0179

0.1961

80

31-38

1642.2

1

0.0609

0.0608

0.1092

0.1961

81

31-38

1616.2

1

0.0754

0.0655

0.194

0.1961

82

31-38

832.6

1

0.4754

0.4653

0.068

0.1961
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different in both raw and normalized data sets. A summary of all 82 of these potential AD
biomarkers is provided in Table 2.1. In addition, each candidate was submitted to receiver
operator characteristic curve analysis. While some of the AD biomarkers were increased/upregulated in quantity, others were decreased in subjects with AD.

2.4.3 Assessment of Diagnostic Similarities between Biomarkers
Correlation analyses of all biomarker pairs were applied to all of the biomarkers. This
resulted in a heatmap, clustering dendogram and correlation matrix that identified markers that
were closely correlated and, hence, provided similar diagnostic information, and those that
showed little correlation and, hence, provided added and complementary diagnostic information.

2.4.4 Evaluation of the Biomarkers in Multi-marker Panels
There is always the potential that changes related to AD may differ from one patient to the
next. This can be due to differences in staging, gender, type of pathology present, and potentially
even its cause. Use of a single biomarker may fail to identify all individuals with a given disease.
Because of this, there is often improved diagnostic ability achieved with appropriate multimarker sets. Hence, the combinations of my serum biomarkers were tested to see if they would
provide better diagnostic discrimination for AD. As discussed in the Methods section, a forward
selection approach was used to construct multiple marker panels. This considered all of the
candidates, recognizing that even biomarkers that were only near significant might add
complementary diagnostic information on patients with AD. All of the normalized biomarkers
that were involved in making multi-marker panels with very high sensitivities and specificities
were also significantly or near significantly different in the un-normalized results. Because
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normalized data suggested fewer candidate biomarkers than raw data, we considered this set
more conservative; in our constructing multi-marker panels, we focused on the normalized data.
Multi-biomarker panels were created by including statistically different or near different
candidates one by one until a combination of the panel yielded the best AUC possible. As
mentioned earlier, each model was considered final when no marker improved the AUC by more
than 0.03. With the construction of these several models, one for each biomarker as the starting
point, it was also possible to determine which of those candidate markers showed up in more
than one model. Markers occurring in several panels were considered to be more robust and
promising among the biomarkers. There were 13 biomarkers that appeared in 10% or more of all
the multi-marker models (See Table 2.2).
Further studies focused on these 13 biomarkers as a subset. Once again, the forward selection
process was done with complementary correlation analysis, which included dendritic analysis
and heat maps. ROC curves were plotted to study the performance of panels of these biomarkers
in identifying AD. The best combinations of the 13 biomarkers provided AUCs of 0.908 and
0.912 (See Figure 2.1 and 2.2). The best combinations provided sensitivities of 88% and
specificities of 87%. There were 6 multi-marker models that had an AUC of more than 0.80,
where 11 of the 13 best biomarkers repeated themselves.

2.4.5 Cluster Analysis
Cluster analysis was done on the subset of 13 biomarkers. Some of these candidates
correlated very well with others in the cluster. This might indicate a common single parent
compound or perhaps represent similarities in biological staging, processes or pathways. The
dendritic analysis suggested that there might be 4 groups (See Figure 2.3).
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Table 2.2. Set of 13 biomarkers that appeared in 10% or more of all the multi-marker models.

Candidate
number

Elution
time
window
(min)

m/z of
biomarker

Charge
(Positive
ion mode)

p value for
ratio of
potential
biomarker
to
reference
biomarker

p value for
log of ratio
of potential
biomarker
to
reference
biomarker

p value for
unnormalized
potential
biomarker

p value for
unnormalized
reference
biomarker

1

11-15

531.3

1

0.0449

0.0414

0.0635

0.4870

2

11-15

602.3

1

0.0905

0.0787

0.1492

0.4870

3

11-15

701.8

2

0.0865

0.0946

0.0684

0.4870

4

11-15

708.3

1

0.0812

0.2063

0.0762

0.4870

5

11-15

892.4

1

0.1487

0.2170

0.0392

0.4870

6

13-19

989.3

4

0.0952

0.1129

0.0940

0.4886

7

16-22

583.3

1

0.0115

0.0379

0.0002

0.3663

8

17-25

804.6

1

0.0550

0.0188

0.0555

0.1461

9

22-32

660.4

1

0.0186

0.0113

0.0579

0.0984

10

29-37

874.6

1

0.1235

0.0044

0.0133

0.4480

11

31-38

1618.2

1

0.0086

0.0119

0.0161

0.1961

12

31-38

810.6

1

0.0044

0.0049

0.0022

0.1961

13

31-38

1568.2

1

0.0018

0.0020

0.0014

0.1961
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Figure 2.1. Multimarker model (ROC curve) for biomarkers 531.3, 1568.2, 804.6, 602.3 and 708.3.
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Figure 2.2. Multimarker model (ROC curve) for biomarkers 1618.2, 804.6, 531.3, 602.3 and
708.3.
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Figure 2.3. Biomarker cluster analysis of 13 AD biomarkers subset.
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2.5 Discussion
My goal was to find biomarkers for AD using a novel serum proteomics approach developed in
my lab. This approach showed success in previous studies done on preterm birth, preeclampsia
and endometriosis (Merrell 2009, Esplin, Merrell et al. 2011, Alvarez 2013). My approach
enabled me to evaluate small proteins, peptides and other bio-molecular species that might show
promise in diagnosing AD. My results suggested that no one molecule was sufficient to diagnose
AD accurately. However, a number of molecules showed significant differences between cases
and controls, and when selected candidates were combined, the best combination was able to
diagnose AD with 88% sensitivity and 87% specificity. Hence, the approach worked and
provided evidence that a serum biochemical diagnosis of AD is possible for most AD patients.
Studies conducted to find diagnostic biomarkers are dependent on the quality and number of
samples available for analysis. I obtained the specimens used in these studies from the Knight
Alzheimer’s Disease Research Center at Washington University School of Medicine. They are
known to have stringent criteria for AD diagnosis and staging. The Knight ADRC ensured that
cases and controls were age and gender matched along with the fraction of subjects with the
APOE e4 allele (a genetic risk factor for AD). Care was taken that patients having co-morbidities
such as diabetes were not included in the study. In this way, biomarkers that overlap with
diseases commonly seen in AD patients (for instance diabetes) can be avoided. It also reduces
the likelihood of discovering biomarkers for general brain disorders. Hence, the biomarkers I
found appear to be specific to AD and not represent any other neurological disease. There is still
the possibility that the changes observed here might occur in other neurologic conditions.
Current understanding suggests that many neurologic diseases share some common features, e.g.,
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increased levels of reactive oxygen species and inflammatory states. Clearly, verification studies
of the biomarkers reported here would be required.
In my approach, I deliberately excluded highly abundant, larger molecular weight proteins
that mask smaller and less abundant species. I recognize that potentially informative species may
have been lost in this approach. Nevertheless, this approach allows for the survey of >8000 low
molecular weight species, and although limited to this subset of serum molecules, it appears to
provide many candidate biomarkers, which may lead to improvements in diagnosis of AD. This
same serum proteomic method has also been previously successful in defining candidate
biomarkers for medical indications, including preterm birth.
Both unnormalized (Abdullah, Paris et al. 2007) and normalized data were used for initial
biostatistical analyses to generate as many candidates as possible. I found more potential markers
using the raw data. This was important to rule out bias that may have arisen from the choice of
corresponding reference markers. It can be difficult to find an ideal endogenous reference
species that is close in m/z value to that of the candidate biomarker and whose quantitative
values among cases and controls look equally distributed. The reference markers were not
statistically different between cases and controls, and seemed to be uniformly distributed.
Normalization removes some of the variability found from run to run. It is noted that all of the
potential biomarkers found after normalization were represented in the set of unnormalized
biomarker candidates. As mentioned, normalization reduced the number of candidates and may
represent a more conservative approach; only those candidates that remained after normalization
were considered in further biostatistical analyses.
Panels of biomarkers were developed using a ‘leave one out’ model, a forward selection
approach. This provided several combinations of markers that had sensitivities and specificities
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above those of single biomarkers. Most of the further analyses were restricted to the biomarkers
that appeared in at least 10% of all the models. Note that this restriction eliminated candidates
found only once in one model, making it less likely to have continued utility. All these
considerations helped reduce the number of candidate markers from 44 significant and 25 near
significant (found using raw MS data) to 38 significant and 21 near significant (found using
normalized data), and of those, to 13 that appeared in at least 10% or more of all multi-biomarker
panels. Using just the 13 candidate markers, I still had 6 panels with acceptable AUCs of 0.80 or
better; of these, two had AUCs above 0.90, both of which provided ~85% sensitivity with ~85%
specificity.
Cluster analysis suggested 4 different groups of related biomarkers. This could indicate: 1)
the clustered biomarkers are fragments of a single parent compound; 2) different clusters may
represent clinical subgroup differences (e.g., gender or disease stage); or 3) different clusters
may possibly reflect different biological processes responsible for, or part of, AD.
In conclusion, the serum proteomic approach used here was able to find novel candidate
biomarkers for AD. Some of these markers appear to be useful diagnostically when used
independently. Combinations of candidate biomarkers allowed a larger portion of AD patients to
be diagnosed. The better panels provided sensitivities and specificities greater than 80%. This
far exceeds any current proposed AD marker or set of markers. Thus, I conclude from these data
that the serum proteomics approach may be a useful adjunct in the serum diagnosis of AD and
also in the study of the pathology of AD.
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CHAPTER 3 - VALIDATION AND CHARACTERIZATION OF ALZHEIMER’S
DISEASE BIOMARKERS

3.1 Abstract
Background: In all, 82 candidate biomarkers with significant and near significant p values,
found in the first study, were further statistically analyzed to develop diagnostic multi-marker
panels. Candidates seen in multiple panels were considered to be more promising. We found that
13 biomarkers appeared in 10% or more of all the multi-marker models. Multi-marker
combinations limited to these biomarkers yielded specificities and sensitivities greater than 80%.
A validation study of these 13 biomarkers was considered critical to determine if any of the
biomarkers continued to hold promise. Further, if candidates were to be useful, chemical
identification of specific biomarkers would be required. Hence, we have sought in this study to
validate these 13 serum AD biomarkers in a blinded replication study analyzing additional
patients and controls, and to find chemical identities of biomarkers with continued utility.
Methods: A blinded validation set consisting of 125 previously unstudied serum samples
including different stages of AD (n = 68) and a similar number of non-demented matched
controls (n = 57) were obtained, processed and analyzed by capillary liquid chromatographytandem mass spectrometry as done in the initial study. The mass spectral data for the 13 AD
biomarkers occurring in several panels as part of the initial study were compiled. Statistical
analysis was performed on individual markers. Combinations of the validated biomarkers were
statistically considered by logistic regression analysis. The validated biomarkers were further
characterized to find their chemical identities using tandem mass spectrometry.
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Results: We found 4 significant biomarkers that continued to be statistically different in the
validation study. Combinations of these were more diagnostic than single biomarker
performance. Also, there were enough very early stage AD patients (CDR = 0.5, n = 24) to
consider them independently. Again, the same 4 biomarkers were significantly different between
cases and controls. Additionally, we were also able to chemically identify these.
Conclusion: These data confirm that the serum proteomic approach has the ability to find
novel serum biomarkers for AD, even in the earliest stage of AD.

3.2 Introduction
Every biomarker discovery study should be followed by a validation study to verify the
usefulness of the candidate biomarkers. A valid biomarker is defined as “a biomarker that is
measured in an analytical test system with well-established performance characteristics and for
which there is an established scientific framework or body of evidence that elucidates the
physiologic, toxicological, pharmacologic, or clinical significance of the test results” (Hunter,
Losina et al. 2010). The validity of a biomarker is highly associated to how it can be
implemented in diagnosis or understanding the disease pathology (Hunter, Losina et al. 2010).
Here, I proposed to use the serum proteomics approach to validate the novel, candidate serum
biomarkers that appeared useful in diagnosing AD. I also focused on finding serum biomarkers
that could aid in very early AD diagnosis. Further, chemical characterization of useful serum
biomarkers was sought as part of these studies. Serum AD biomarkers diagnosing early stage
AD should allow for evaluation of promising AD drugs much more efficiently and may be useful
in personalized drug therapies.
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3.3 Materials and Methods

3.3.1 Procurement and Storage of Samples
A validation study of the previously found biomarkers was proposed to the Knight ADRC at
Washington University School of Medicine, and permission was granted for my procurement of
a new set of serum samples. A set of 125 samples was provided. These comprised 68 cases
constituting different stages of AD and 57 controls that were non-demented and matched for age,
gender and ApoE 4 prevalence. Among 68 cases, I had 24 samples with CDR = 0.5. This made it
possible for me to test the performance of my biomarkers between non-demented controls (CDR
= 0) and individuals with mild cognitive impairment (CDR = 0.5). This comparison was not
possible in the first study due to the very small number of samples with CDR = 0.5 in that set.
An intermediary, aware of case/control status, created analysis sets that included both cases and
controls randomized and submitted to my laboratory analysis in a blinded fashion. A total of 11
sets of samples, consisting each of 10-13 sera, were analyzed. The sets had approximately the
same number of cases and controls as well as the same number of men and women to avoid bias
due to sample processing, day to day changes in instrumental sensitivities, loading and ionization
inefficiencies. All MS data were provided to the intermediary for statistical analysis independent
of the laboratory investigators having any knowledge of case/control status. The samples were
shipped on dry ice and stored at−80°C pre and post processing.

3.3.2 Validation of Biomarkers
Only one analysis set was processed at a time. Specimens were processed, subsequently
loaded, and analyzed using as Agilent 6530 Accurate-Mass Q-TOF LC/MS mass spectrometer
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system as part of a single day. All sets were analyzed in as short a time as possible to minimize
chromatographic and instrumental variation. A 45-min wash was included between each sample
to minimize any carry over effect while a more significant wash of 105 min was added at the end
of every day. Great care was taken to maintain consistency in sample processing, quantitative
loading, chromatographic elution profile and instrument calibration/sensitivity performance
across all specimens and all days. Samples were processed using acetonitrile precipitation as
described in Chapter 2 under the Methods section.
An Agilent 1260 Infinity Series HPLC system equipped with quaternary pump, online
degasser, auto sampler, and thermostated column compartment (Agilent Technologies, Karlsruhe,
Germany) was used to perform these validation experiments. Injection volumes of 5 µL,
containing an apparent protein concentration of 5 µg were injected onto a 1 mm (16.2 µL)
microbore guard column from Upchurch Scientific, Oak Harbor, WA, to retain specimen and
eliminate salts and highly polar compounds. The guard column was then placed in series and
sample loaded onto and fractionated by the analytical column (15 cm x 250 µm i.d. POROS R1
reversed-phase capillary column; media was obtained from Applied Biosystems, Framingham,
MA, and columns were packed in-house) with a mobile phase flow rate of 5 µL/min. Mobile
phase A was an aqueous solution water/acetonitrile/formic acid (98:2:0.1, v/v/v) and mobile
phase B was primarily organic solution containing acetonitrile/water/formic acid (98:2:0.1,
v/v/v). The gradient elution began at 100% A for 2 min followed by a 1 min transition from
100% A to 95% A. This in turn was succeeded by a linear increase in organic phase (B) to 60%
over the next 24 min. Thereafter, the mobile phase mix was increased linearly to 95% organic
phase B/5% aqueous phase A over the next 7 min, then held at 95% organic phase B for 7 min
and returned to 95% aqueous phase A over 5 min. The column was allowed to re-equilibrate
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until the end of the 58 min run.
In the cLC-MS system, the cLC was interfaced with an Agilent 6530 accurate-mass
quadrupole time-of-flight mass spectrometer (QToF MS) equipped with an Agilent Dual ESI
source. The Dual ESI source was operated in the positive ion mode, and instrument parameters
were set as follows: sheath gas temperature, 300°C; sheath gas flow, 5 L/min; nebulizer, 15 psi;
dry gas temperature, 300°C; dry gas flow, 5 L/min; and capillary entrance voltage (VCap), 3500
V. Fragmentor and Skimmer 1 were operated at 175 V and 65 V, respectively. The auto sampler
temperature was maintained at 4 °C. The MS scan data were collected at a rate of 8 spectra/s
over the range of m/z 400–3200. Data were acquired in profile mode. The instrument software
MassHunter Data Acquisition B.05.01 (Agilent) and MassHunter Qualitative Analysis B.06.00
(Agilent) permitted effective data collection, extracting specific ion chromatograms and post hoc
analysis.

3.3.3 Fragmentation and Chemical Identification Studies
Fragmentation and chemical identification of biomarkers were accomplished using an
MS/MS approach with a QSTAR Pulsar I quadrupole orthogonal time-of-flight mass
spectrometer and Agilent 6530 accurate-mass Q-TOF LC/MS. Primarily peptides were
sequenced using a QSTAR Pulsar I quadrupole orthogonal time-of-flight mass spectrometer
while lipid identifications were performed using both instruments.

3.3.3.1 Peptide Fragmentation Experiments Employing Applied Biosystem’s QSTAR
Pulsar I Quadrupole Orthogonal Time-of-Flight Mass Spectrometer
The cLC system was interfaced to a QSTAR Pulsar I quadrupole orthogonal time-of-
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flight mass spectrometer through an ESI IonSpray source (Applied Biosystems) set at 4800 V.
All experiments were carried out in the positive ion mode and the instrument parameters were set
as follows: sheath gas temperature, 25°C; nebulizer gas temperature, 25°C; nebulizer gas
pressure, 20 psi; curtain gas pressure, 24 psi and electrospray voltage, 4800 V. The autosampler
temperature was maintained at 4 °C. Either unit or low resolution was generally used. Samples
run earlier were examined to find samples that naturally had a high concentration of the
biomarkers of interest. Samples were processed using acetonitrile precipitation and loaded as
described in Chapter 2. Prior to MS2 runs, MS1 runs were undertaken to determine the elution
time. For MS2 runs, an increased amount of protein-depleted serum was loaded to enable
detection of the lower intensity fragment peaks clearly. Samples were manually injected and
MS/MS fragmentation data were collected from m/z 50 up to 2000 depending on the initial m/z
value and charge state of the precursor ion. The total run time was 55 min with a mass spectral
scan rate of 1 spectrum/s. The delay time feature was used and fragmentation was only done
during the relevant 2 min elution window. This 2 min window was begun 1 min before and
ended 1 min after the biomarker peak. Either argon (Q-Star) or nitrogen (Agilent) was used as
the collision gas. Typically, 2-4 runs at different fixed collision energies were performed to
obtain the broadest set of fragments for the peaks of interest. Different spectra from different
runs were first overlaid and then added using the Add Data feature in the Analyst QS 1.1
instrument software, yielding a summed MS2 spectrum.

3.3.3.2 Peptide Sequencing via the Mascot Search Engine
I manually analyzed each mass spectrum and exported the peak m/z values and intensities to
an Excel sheet. Here, any incorrectly assigned charge states were corrected by comparing these
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peaks to the fragmentation data in the mass spectrum. All the peaks with charge state more than
1 in the adjusted data list were converted into their +1 m/z values using the formula: +1 mass =
m/z value x charge – (charge – 1 H+) to simplify the database search. This amended list of ions
was pasted into a Mascot generic format file and submitted to Mascot
(www.jp1.chem.byu.edu/mascot - departmental mascot subscription). The “.mgf” file was
uploaded, and the parameters used for Mascot searches were: no enzyme digestion, Uni_human
database, no modifications, peptide tolerance of 1.2 Da, and MS/MS tolerance of 0.6 Da. Protein
Blast search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was typically used in an effort to identify
the parent protein compound for the peptides.

3.3.3.3 De Novo Sequencing of Peptides
On several occasions, Mascot has not generated conclusive results. This is often due to
incomplete b- or y-ion series. In such cases, de novo sequencing was performed, where the
fragmentation spectrum is manually evaluated to assign amino acid identities by studying the
mass differences between fragment ions. There are typically both b- and y-ions observed when
collision-induced dissociation is performed. Interpretation can be complicated when both
incomplete representation of b and y ions are produced. First, I attempt to identify the b1 and/or
y1 ions to specify the starting point of the peptide sequence. Immonium ions found in the low
m/z range (typically < 200) often give indications about the amino acids present in the peptide
sequence. Beginning with b1 or y1, mass differences between neighboring or near neighbor
peaks in the MS2 spectra were studied. When a mass difference corresponded with the mass of
an amino acid residue, I identified the next amino acid. Then that peak was used as a reference,
and the process was repeated to assign the next amino acid in the series starting from the b2 or
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y2-ion fragment peak. This continued until a sequence of all amino acids contained in a peptide
was ascertained. Several different partial combinations were sometimes obtained during the
process. Often, with multiple collision energies and careful assignment, a tentative sequence was
obtained. This could be compared to known amino acid sequences using a BLAST search for all
proteins in the human using the NIH database. If the amino acid sequence was incorrect, no
matches were found. With small peptides, the amino acid sequence may not be unique to a single
parent protein. Usually, when something looked irresolvable by this approach, I checked for
possible amino acid modifications. Occasionally, when a sequence could not be determined
completely by de novo sequencing, the parent protein could still be determined using the protein
BLAST search knowing that there must be a shared partial sequence and that the peptide’s total
mass must still be consistent with the mass of possible extended peptides from any protein that
contains that partial sequence (Alvarez 2013).

3.3.3.4 Lipid Identifications Employing Applied Biosystem’s QSTAR Pulsar I Quadrupole
Orthogonal Time-of-Flight Mass Spectrometer
Fragmentation studies for lipids and their identification were carried out using the same
instrument parameters as described in peptide identification studies above. The primary
difference was that 1 or 2 collision energies were sufficient for fragmenting lipids.
Fragmentation remained quite consistent across different collision energies and typically showed
a very high intensity peak representing the head group.
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3.3.3.5 Lipid Fragmentation Experiments Employing the Agilent 6530 Accurate-Mass QTOF LC/MS System
The Dual ESI source was operated in the positive ion mode and the instrument parameters
were set as follows: sheath gas temperature, 300°C; sheath gas flow, 5 L/min; nebulizer, 15 psi;
dry gas temperature, 300°C; dry gas flow, 5 L/min; and capillary entrance voltage, 3500 V.
Fragmentor and Skimmer 1 were operated at 150 V and 65 V, respectively. The autosampler
temperature was maintained at 4°C. The MS scan data were collected at a rate of 1 spectrum/s
over the range of m/z 110–2000. Data were acquired in both profile and centroid modes. A
reference solution having ions at m/z 121.0509 and 922.0098 was used during these experiments.
Reference nebulizer pressure was maintained at 5 psi while auto calibration reference parameters
were: detection window, 20 ppm, and minimum height, 1000 counts. The reference standards
allowed me to correct unknown masses and also allowed me to determine the day-to-day drift in
mass accuracy to ensure that no instrument adjustment needed to be made. In the case of lipids,
where exact mass really matters, this was an important tool. The software, MassHunter Data
Acquisition B.06.00 (Agilent) and MassHunter Qualitative Analysis B.05.01 (Agilent), permitted
direct on-line data collection, extracting specific ion chromatograms and analysis.
Data-dependent Auto MS was most commonly used for fragmentation studies. However, if
peak intensities were low, representing too few MS2 scans, then data independent targeted MS
was also used. The MS and the MS/MS information were collected from m/z 50. The ending m/z
value depended on the mass of the parent lipid molecule, ensuring that the range would include
all fragments of the parent lipid molecule. Typically, collision energies ranging from 15-30 eV
were used for fragmentation. Not more than 3 different collision energies were used per run.
Sometimes, a single collision energy was sufficient to obtain good fragmentation, while other
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times additional energies were needed. The isolation width of the precursor ion was set to be
narrow (∼1.3 m/z). A narrow width precluded the possibility of fragmenting neighboring peaks.
Typically, MS scan rates and MS/MS scan rates were 1 spectrum/s, although in a few cases, scan
rates of 2 spectra/s were used. With a lower scan rate, more of the transients hit the detector;
hence, there was an increase in the gain, which helped in obtaining higher signal/noise ratio of
the fragment ions. Data were collected in both centroid and profile modes.
3.3.3.6 Identification of Lipids
While fragmenting some of our candidate biomarkers, a prominent peak at m/z 184.07 was
observed. This is indicative of a phosphocholine head group, a distinctive feature of one class of
glycerophospholipids. With lipids, there were not as many fragments as typically seen in peptide
fragmentation spectra. Increasing the collision energies did not mean more fragmentation, but
mostly just an alteration of peak intensities for the fragments that were already seen.
To further characterize lipid biomarkers, a search was performed on Lipidmaps
(lipidmaps.org), the primary database of known lipids. The search involves using the mass of the
neutral precursor ion ((M+H+) – H+). Fragmentation data are not available and fragmentation
spectra cannot be compared with archived data, because no fragmentation patterns exist.
Consequently, the database would typically provide several compounds having similar masses
from very close in m/z to others more unlikely. We focused only on the ones closest in m/z to the
molecule of interest. Second, I only considered those classes of lipids that contained the observed
head group. For instance, if a phosphocholine head group was observed in the spectrum, only
phosphocholine lipids were considered. This typically limited the candidates dramatically. Then,
more careful analysis of the MS2 fragments was conducted, looking for fragments representing
fatty acids that modified the glycerol backbone. This was often successful but did not allow
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assignment of fatty acids to the sn1 or sn2 positions on the glycerol. In cases of lipid oxidation, it
appeared to be unsaturated fatty acids that were modified; however, in the MS2 fragmentation,
the oxygen containing fatty acid did not remain intact. Occasionally identification was achieved
from published studies where known lipids had been studied by MS2 and fragmentation patterns
were unambiguously the same as for the lipid biomarker. This was infrequent as there are very
few reports of this nature.
Even after narrowing the field of possibilities as just described, there are almost always
multiple lipids that share the same mass. The location of fatty acid substituents on the glycerol
backbone cannot be determined by mass spectrometry, nor can the location of double bonds be
determined by MS. There are double bond locations that are far more naturally frequent among
fatty acids, but this cannot be determined. Given the very low abundance of these biomarkers, no
other instrumental method, e.g., NMR, is possible. LIPID MAPS MS does provide a software
tool (http://www.lipidmaps.org/tools/index.html) that predicts the fragments based on parent
mass and sn1 and sn2 acyl chain information. However, this does not allow for the determination
of sn1or sn2 location or position of double bonds within fatty acid components. Standards of
possible compounds are not typically available. Researchers have previously reported data
regarding the positions where the fragments can break from a glycerophosphotydylcholine
molecule (Byrdwell 2005). This information was used to predict various different fragments
possible for the choices I had. Some of these would be ideally seen in the MS2 spectrum for
confirmation (Alvarez 2013).
Some of my biomarkers were oxidized lipid molecules, and certain fragments indicative of
loss of oxygen were observed. In case of hydroxylated species, most of the fragment ions have
odd number m/z values and fragmentation resulted in neutral water loss. For others, a neutral
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loss of 16 would represent a keto or epoxide modification. However, these attempts don’t
typically provide the exact location(s) of the modifications or whether the fatty acid occupied the
sn1 or sn2 position. These oxidized lipids represent the effects of reactive oxygen species
generated by oxidative stress in subjects. Oxidized lipid molecules are not found in the
Lipidmaps database. Their fragmentation spectra are also more complicated compared to other
lipids, and very few publications include MS2 data.

3.3.4 Statistical Analysis Including Construction of Multi-marker Model Using Validated
Biomarkers
Simple statistics (Student’s t-test) were used to evaluate the performance of the 13 candidate
markers in this replication study. A p-value < 0.05 was considered significant. The biomarker
also had to show the same trend comparing cases to controls. Different combinations of the
statistically significant candidate biomarkers were further studied to find out if they provided
better diagnostic discrimination. Logistic regression analysis was used to consider combinations
providing a receiver operator characteristic curve (plot of sensitivity, i.e., true positive versus 1specificity, i.e., true negative) from which could be calculated an area under the curve and a
sensitivity at any given specificity.

3.4 Results

3.4.1 Validation of Previously Found Biomarkers that Showed Significant Diagnostic
Discrimination
I focused initially on how well the 13 biomarkers that had performed most consistently in the
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initial serum AD biomarker study performed in this validation study. Of these 13, the biomarkers
m/z 708.3 and 660.4 were not clearly seen in most of the current samples. In the case of m/z
708.3, in the validation set, there was a large, unrelated peak that likely led to ion suppression.
Moreover, there was also in these specimens an overlapping peptide envelope, which made
calculation of the target molecule impossible. For peak m/z 660.4, the intensity was too low to
determine peak height or area with confidence. Hence, these two could not be analyzed.
The extracted MS data obtained for the remaining biomarkers were sent to the independent
mediator who conducted the analyses and maintained the blind. The data were tested in four
ways: 1) non-demented, matched controls (CDR = 0) vs. any stage AD cases, i.e., a CDR 0.5 or
greater); 2) matched, non-demented controls (CDR = 0) vs. CDR > 0.5 (this excludes the earliest
stage AD patients); 3) matched, non-demented controls (CDR = 0) compared with patients
having moderate AD (CDR = 2); and finally 4) matched, non-demented controls (CDR = 0) vs.
the earliest stage AD only (CDR = 0.5).
Among the remaining 11 biomarkers, m/z 602.3, 804.55 and 874.6 were significantly
different between cases and controls for all 4 comparisons and followed the same trend as
observed in the original study.
As I reviewed data from the initial study, I found that there were 2 candidate biomarkers with
the same nominal m/z of 804.5, but offset somewhat in elution time from the 804.55 that was
validated. To ensure that there was no misinterpretation of the data, both species were included.
The second species had an m/z of 804.53, but eluted later between 39.5-41.5 min (compound
with m/z 804.55 eluted between 33-35 min). This species had been a significant biomarker in the
initial data, but was not part of the subset of 13. The candidate at m/z 804.53 in the later
hydrophobic region also passed the validation. Cases had significantly higher quantities

78

compared with controls in the validation set as in the preliminary study. (See Table 3.1 for all
results of the validation of these biomarkers). Among the validated biomarkers, all were higher
in cases. This applied when I did comparisons between different stages of AD for these
biomarkers as well.
As part of the chemical identification studies, it was noted that the candidate with m/z 810.6
representing a protonated species was also present as m/z 832.6 representing a sodiated species
[M+Na+]. The peak m/z 832.6 was also a candidate biomarker in the initial study and belonged
to the list of significant and near significant biomarkers. Hence, I extracted data for the peak at
m/z 832.6 as well and included it. Also, I summed the data for the two ionic species m/z 810.6
and 832.6 as they represented the same biomolecule. Individually and collectively they did not
validate.
In a somewhat similar situation, as fragmentation studies were conducted the candidate m/z
989.3 was found to represent a peptide in its +4 charge state. The same peptide also occurred in
its +3 charge state (m/z = 1318.7) and, hence, both ion species were extracted and results of both
charge states were considered individually and combined. However, whether considered
individually or in combination, this peptide was no longer quantitatively different between cases
and controls in the replication study.

3.4.2 Identification of the Validated Biomarkers
The 4 biomarkers that validated in the replication set became the focus of efforts to
chemically identify them. Broadly, this was successful. Preliminary work demonstrated that 1 of
these was a peptide and 3 were glycerophosphocholine lipids. The structural features that can be
obtained from MS studies are summarized for each of the 4 biomarkers as follows.
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Table 3.1. Student’s t-test results showing p values obtained for the unnormalized
validation data. Different stages are compared and p values for them are listed in the table
as well. Trends indicating whether values were higher in cases or controls were also studied.
Observation was made if they followed the same or opposite trend. Finally, in the last
column, indication is given as to whether or not the biomarker passed the validation study.
Number/
Comments

Z

1

Biomarker
(m/z)
531.3

CDR 0 vs
CDR >0

CDR 0 vs
CDR >0.5

CDR 0 vs
CDR 2

CDR 0 vs
CDR 0.5

Trend

1

Retention
Time
(min)
19-21

0.5669

0.3645

0.6203

0.1037

602.3

1

19.5-22.5

0.0014

0.0584

0.0465

8.41x10-5

Not
applicable
Same

2
3

701.8

2

19-21

0.3251

0.2837

0.8336

0.6766

4

892.4

1

18.5-20.5

0.5819

0.6021

0.5393

0.7325

5

989.3

4

21.5-23.5

0.0586

0.0691

0.0787

0.2012

Same
molecule

1318.7

3

21.5-23.5

0.4336

0.3900

0.3264

Values
combined

989.3+1
318.7

0.0709

0.0787

6

583.3

1

28-30

0.1010

7

804.6

1

33-35

8

874.6

1

9

810.6

Same
molecule

832.6

Values
combined

810.6+8
32.6

10

1568.2

1

11

1618.2

12

804.5

Validation
Status
Failed
Passed

Not
applicable
Not
applicable
Opposite

Failed

0.6888

Not
applicable

Failed

0.0877

0.2321

Not
applicable

Failed

0.2172

0.0200

0.0727

Opposite

Failed

3.60x10-7

2.40x10-7

2.00x10-5

1.75x10-8

Same

Passed

40-44

6.37x10

0.0006

0.0025

3.00x10

Same

Passed

1

45-48

0.4717

0.4593

0.9367

0.6800

Failed

1

43-46

0.2827

0.5921

0.4973

0.0489

Not
applicable
Not
applicable

0.3948

0.4181

0.9792

0.5536

Not
applicable

Failed

44-47

1.66x10-5

0.0001

0.0142

0.0115

Failed

1

44-47

0.9239

0.6117

Opposite
but same
for mild vs.
severe AD
Same

1

39.5-41.5

9.48x10

Same

Passed

-5

-7

3.68x10
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0.0835
-6

1.34x10

-5

0.3607
-5

1.36x10

-6

Failed
Failed

Failed

Failed

Biomarker 602.31 (charge state = 1) is a peptide with sequence of amino acids L/IAENR.
The parent protein cannot be unambiguously identified. This sequence is found in several
proteins. (See Table 3.2.). The observed fragments can be seen in the fragmentation mass
spectrum (See Figure 3.1).
Biomarker 804.55 (charge state = 1, 33-35 min) is a phosphatidylcholine with two fatty acid
acyl side chains, one having 18 carbon atoms and 2 double bonds (18:2) and the other having 20
carbon atoms and 5 double bonds (20:5). The positions of the double bonds are not determinable.
A high intensity fragment seen at m/z 542.3211confirms the presence of a fatty acid (18:2), and a
high intensity fragment observed at m/z 520.3342 confirms the presence of a fatty acyl chain
(20:5) (See Figure 3.2). The molecular formula for the lipid molecule is [C46H78NO8P]+H+.
Biomarker 874.59 (charge state = 1) is a peroxidated phosphocholine lipid molecule. In such
cases, it is difficult to determine fatty acyl side chains that have been oxidized. However,
reference to the literature provided a match, and from that I obtained a formula for this molecule,
PC (38:4)-(OOH)2. It is an oxidatively modified lipid representing the bis-peroxide the two fatty
acids 18:0 and 20:4 in glycerophosphatidylcholine (810 + 64) with elemental composition of
C46H84NO12P (Ingram, Homer et al. 2003). Given the saturated nature of one fatty acid (stearic
acid), it is almost certain that the oxidation is of arachidonic acid, containing 4 double bonds.
Figure 3.3 shows the fragmentation spectrum of 874.59.
Biomarker 804.53 (charge state = 1 eluting at retention time 39.5-41.5 min) is an oxidized
glycerophosphatidylcholine molecule of molecular composition [C42H78NO11P+H+]. Again,
saturated palmitic acid (16:0) is one of the fatty acids modifying the glycerol backbone and not
subject to oxidation. The second fatty acid (18:2), containing double bonds, was oxidized
(Pereira 2006). It is likely that the second chain contains one peroxide and one keto group.
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Figure 3.4 shows the fragmentation spectrum of 804.53.

3.4.3 Constructing Multi-marker Diagnostic Panels for AD
Logistic regression analysis was performed to evaluate the ability of multi-marker models to
diagnose AD. They were attempted for any stage AD as well for the very earliest stage of AD
(CDR = 0.5). This same statistical approach was also used in the original study, but was
supplemented with other statistical comparisons. In this approach, all possible combinations of
the 4 biomarkers were considered. Additionally, all 4 biomarkers were included in one model.
The analysis provides a receiver operator characteristic plot of the performance of the model in
correctly identifying cases (sensitivity) as a function of the false positive rate (1-true negative
rate/specificity). When comparing controls (CDR = 0) vs. any stage AD cases (CDR = 0.5, 1.0,
2.0), the best model was obtained by using all four biomarkers as shown in Figure 3.5 with an
AUC = 0.7865. When comparing controls (CDR = 0) vs. very mild stage AD (CDR = 0.5), the
best multi-marker panel is the combination of biomarker m/z 804.6 and biomarker 602.3 as
shown in Figure 3.6 with AUC = 0.8502. If all 4 biomarkers are included in the panel for early
stage AD diagnosis, then a panel with AUC = 0.8494 is obtained as shown in Figure 3.7.

3.5 Discussion
It should be noted that for the validation study, an Agilent 6530 Accurate-Mass Q-TOF
LC/MS system was used, which was different from the instrument used during the initial study.
This was due to significant problems with the QStar instrument that occurred during the
validation study. This made the instrument erratic and unusable for quantitative comparisons in
the validation study. The Agilent instrument is, nonetheless, a capillary liquid chromatography
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Table 3.2. Table of calculated and observed b and y ions, confirming the sequence L/IAENR for the
biomarker peptide 602.3 (charge state 1).
Amino acids
L/I

Calculated b
ions
114.0919

Calculated y
ions
602.3262

Observed b
ions
Absent

Observed y
ions
602.3079

A

185.1291

489.2422

185.1247

489.2442

E

314.1716

418.2051

314.1593

418.1749

N

428.2146

289.1625

428.2129

289.1574

R

584.3157

175.1196

584.2684

175.1022
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ions
86.0878

	
  

Figure 3.1 MS/MS spectrum revealing fragment ions of molecule m/z 602.31.
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Figure 3.2 MS/MS spectra revealing fragment ions of molecule m/z 804.55 (second spectrum
zoomed in to show fragments 520.3342 and 542.3211).
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Figure 3.3 MS/MS spectrum revealing fragment ions of molecule m/z 874.59.
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Figure 3.4 MS/MS spectrum revealing fragment ions of molecule m/z 804.53.
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Figure 3.5. Receiver operator characteristic curve with AUC 0.7865 for diagnosis of AD using all 4
validated biomarkers 602.3, 804.6, 874.6, 804.5. The curve represents biomarkers that looked
different between non-demented controls (CDR = 0) vs. any stage AD (CDR = 0.5, 1.0, 2.0). The
numbers shown in the curve are observation numbers.
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Figure 3.6. Receiver operator characteristic curve with AUC 0.8502 for early diagnosis of AD using
biomarkers 602.3 and 804.6. The curve represents biomarkers that looked different between nondemented controls (CDR = 0) vs. very mild stage AD (CDR = 0.5). The numbers shown in the curve
are observation numbers.
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Figure 3.7. Receiver operator characteristic curve with AUC 0.8494 for early diagnosis of AD using
all 4 biomarkers 602.3, 804.6, 874.6 and 804.5. The curve represents biomarkers that looked
different between non-demented controls (CDR = 0) vs. very mild stage AD (CDR = 0.5). The
numbers shown in the curve are observation numbers.
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system with electrospray ionization introduction of specimen onto a quadrapole-time-of-flight
instrument. Instrumental parameters and methods were made as close to the original as possible.
My total ion chromatograms looked similar to what was observed in the original study. The
Agilent system was new and has sub 1 ppm mass accuracy, mass resolution of >20000 and high
femtogram sensitivity that is superior to the older QStar instrument used in the previous study
(https://www.chem.agilent.com/Library/brochures/5989-9397EN_LO.pdf). The retention times
and peak intensities appeared to be very consistent using this instrument compared with the
previous instrument. If anything, these results should be more accurate and consistent.
The validation studies were done to verify the utility of previously found biomarkers. This
study was performed in my lab in a blinded fashion where involved researchers did not know the
case or control status of the subjects from whom the specimens were collected.
The validation results were successful and showed several candidate biomarkers that
continued to show significant differences between cases and controls. While individual markers
may be useful in AD diagnosis, additional diagnostic power was sought through the development
of biomarker panels. Utilizing accepted statistical approaches, a diagnostically useful
combination of biomarkers was constructed, the current optimum giving an AUC of 0.8502 for
the diagnosis of the earliest stage of AD. It showed a sensitivity of ~83% for a specificity of
~78% or ~75% sensitivity at a specificity of ~85%. It would be interesting to evaluate the
performance of these biomarkers taking into account other clinical or demographic features (for
example, the effect of gender), but this would require much more substantial clinical information,
which currently is not available. Nevertheless, these results are substantially better than any
existing validated AD diagnostic approaches. Currently, there is no ability to biochemically or
radiologically diagnose early stage AD. Also, it should be remembered that there were many
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additional candidates in the original study that could also be explored in the validation set, which
may add to the capability of diagnosing AD.
Tandem MS fragmentation studies to chemically identify biomarker candidates have allowed
me to identify statistically significant peptide and lipid biomarkers to the extent that can be
accomplished instrumentally. Of the 13 biomarkers considered here, 5 appeared to be peptides.
Among the other 8 biomarkers, 7 appear to be lipids, which contain a phosphocholine group. Of
the 13, 2 biomarkers could not be evaluated. An overlapping peptide envelope hid biomarker
708.3. Additionally, abundant neighboring peaks caused ion suppression and lowered the
intensity of this biomarker in the majority of the samples. Biomarker 660.4 was of such low
intensity in specimens in the validation set, that it could not be accurately quantified. Of the 4
validated markers, the peptide at m/z 602.3 has been sequenced, but is too small to assign a
parent protein unambiguously. I have also characterized the lipid biomarkers as fully as can be
accomplished with current instrumentation and methods. Work to better understand
fragmentation of oxidized lipids will continue independently in my lab, making use of standards
exposed to oxidative reagents. However, those are envisioned studies and not complete. Of
interest, two of these validated biomarkers represented lipid oxidation products.
Research has shown that oxidative stress and lipid peroxidation may be contributing factors
to AD pathology, leading to neuronal loss and mitochondrial dysfunction. These factors are
predicted to be involved in the actual pathogenesis of AD during its very earliest stages (Jenner
1991, Beal 2003). One study done on a rat model of AD showed that brain tissue from these
animals had a reduction in cardiolipin resulting from lipid peroxidation in the mitochondria
exposed to free radical stress in the animal (Ruggiero, Cafagna et al. 1992). It has also been
reported that the cardiolipin biosynthesis pathway may be selectively compromised by oxidative
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stress, causing approximately 20% reduction and a change in composition of the cardiolipin
content (Ellis, Murphy et al. 2005). Oxidized phospholipids are involved in other
proinflammatory pathologies as well as in response to immunologic mechanisms. Although there
has been tremendous research concerning oxidized phospholipids as a general phenomenon
(Greig, Kennedy et al. 2012), individual phospholipids have not been studied. With more
extensive research on these biomarkers, it might be possible to obtain more detailed information
about the biology of these altered biomarkers and their potential role in the pathology of AD.
Recently, Mapstone et al. discovered and validated ten lipid peripheral blood biomarkers that
predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer’s disease
within a 2–3 year timeframe with over 90% accuracy (Mapstone, Cheema et al. 2014). Most of
these would normally be considered small metabolites. However, there were no oxidized
phospholipids among these, which might serve to be better predictors of early stage AD. My
approach is unique and serves to find lipid as well as peptide biomarkers, which may provide
greater detail about disease presence and staging. My results should at a minimum be considered
complementary to Mapstone’s.
To conclude, my research verified the utility of several, novel biomarkers found to diagnose
AD in the previous study. These markers have been as completely identified as can be
accomplished scientifically by MS or by any other method given the nanomolar concentrations
of these biomarkers. How or why these species are found in the circulation system is of interest,
including exploration of where they originate in the body; however, such questions are beyond
the scope of this research. Importantly, biomarkers specific to very early AD were found,
consistent with the results reported in Chapter 5. Consideration of markers observed there as well
as gender considerations as described in Chapter 4 may prove interesting in follow up studies. In
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summary, this low molecular weight, serum proteomics approach discovered and validated novel
diagnostic biomarkers for AD, even early stage AD.
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CHAPTER 4 - IDENTIFICATION OF GENDER SPECIFIC BIOMARKERS FOR
ALZHEIMER’S DISEASE

4.1 Abstract
Background: Approximately two-thirds of Americans with AD are females as reported by the
Alzheimer’s Association. There is also anecdotal data that the course of AD in women is more
aggressive. These observations suggest that there are likely gender differences in AD, but at
present, no study has sought biomarkers that differ among men and women with AD or that are
more specific to AD in women or in men. We predict there are biomarkers that are unique to
males versus females. This could not only be important during diagnosis, but also when studying
the pathways involved in AD. Hence, we attempted to restudy the biomarkers we found in allstage AD cases versus matched controls, but consider potential differences based on gender.
Methods: Serum samples from 58 cases from individuals with any stage AD and 55 matched
controls were depleted of high abundance, high molecular weight proteins, fractionated by
capillary liquid chromatography and analyzed by ESI-MS. This has yielded 38 statistically
significant biomarkers with another 21 near significant biomarkers. The data for males and
females were separated into sets for these studies: 1) 29 male cases vs. 26 male controls, and 2)
29 female cases vs. 29 female controls. The biomarkers found in the initial study were
reexamined in these sets to see if they were either male or female specific. Simple t-test
statistical differences were determined as well as logistic regression analysis to test their
diagnostic sensitivities and specificities.
Results: First, we found 31 significant (p < 0.05) or near significant (p = 0.05 to 0.099)
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biomarker candidates for women and, second, we found 16 significant or near significant
biomarkers for men. Additionally, 25 significant or near significant biomarkers were found to
perform equivalently for women and men. Panels of markers specific for either women or men
provided sensitivities of 60-70% with specificities >85% for diagnosis of AD.
Conclusion: This serum proteomics approach was successfully used to find gender-specific
serum biomarkers for Alzheimer’s disease.

4.2 Introduction
Alzheimer’s disease is twice as prevalent in women as in men. As a function of age, the
differences in AD incidence in women become even more substantial (Andersen, Launer et al.
1999, Lobo, Launer et al. 2000). Not only is there a higher probability of women getting AD,
they also demonstrate greater cognitive declines compared with men. This even includes verbal
skills that are stronger in healthy females compared with males (Hyde and Linn 1988, Weiss,
Kemmler et al. 2003, Maylor, Reimers et al. 2007, Wallentin 2009).
In the Religious Orders Study (participants were older catholic nuns, priests and brothers),
141 brains were studied postmortem. It was reported that in women the association between the
severity of AD pathology and clinical manifestations of AD were 20 times stronger compared to
men (Barnes, Wilson et al. 2005). They concluded that AD tissue pathology would be diagnosed
with clinical dementia much more frequently in women than in men. This conclusion concurs
with the numerous reports stating the incidence of AD being higher in women than in men
(Andersen, Launer et al. 1999), possibly because of longer life span (Hebert, Wilson et al. 2000).
Researchers compared both genders with equally severe AD using results of 18FDG-PET
imaging. They found that women had significantly elevated glucose metabolism in the sections
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principally associated with the pathological process of AD, i.e., the right inferior frontal, superior
temporal and insular cortices, and the hippocampus, compared with men. This suggests again a
gender difference in the disease process (Perneczky, Drzezga et al. 2007). In these studies, I
sought to find serum biomarkers that confirmed a gender difference between AD women and AD
men. This may allow me to define the biochemical pathways involved.
If there are gender differences in AD and in AD biomarkers, the most straightforward
explanation would be hormone-driven differences. The metabolic changes caused by hormones
may affect the pathology of AD. Estrogen is known to protect the brain. The decrease in the
female hormones during menopause may reduce metabolism in the brain. This might increase
risk for AD. Despite both sexes having receptors present for both estradiol and testosterone, their
brains respond very differently to the hormones. Similarly, even though both sexes can
synthesize estradiol in neurons, synaptic responses are sexually dimorphic in different regions of
the brain. These studies demonstrate gender differences in brain biology and imply that the
pathogenesis of AD will require deeper comprehension of the intricate interplay of genetics,
hormonal regulation and environmental factors. The role of gender differences in the onset and
progression of AD remains poorly understood, but is undoubtedly important (Carter, Resnick et
al. 2012).
Longevity likely contributes to the higher fraction of women having AD compared to men
beyond the age of 80 years. Longevity does not explain the higher number of AD cases among
women between 60-80 years. There is currently effort to define potential pathogenic
mechanisms to explain these findings. In one study, the authors noted that the mitochondria
from young females are safeguarded against amyloid-β protein toxicity, produce fewer reactive
oxygen species, and generate fewer apoptotic signals than males. But this was not the case for
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mitochondria from older females (specifically during/post menopause). Clearly, these results
suggest that estrogenic compounds and responses protect against the mitochondrial toxicity of
amyloid-β protein (Viña and Lloret 2010). However, the issues are not simple. Studies of
estrogen replacement therapies have not generally been successful in protecting against AD.
Moreover, while all women eventually go through menopause, not all of them develop AD.
Finding gender specific AD biomarkers holds open the possibility that more specific and more
complete mechanisms involved in AD as a result of gender differences may be found.
Hence, I proposed to use the serum proteomics approach to look for biomarkers that might be
useful to diagnose AD specifically among men or women. In turn, such gender specific
molecular expression differences might identify gender differences in pathway involvement and
may be useful in developing treatments for AD that are more effective in women or men.

4.3 Materials and Methods
As described in Chapter 2, serum specimens were obtained from the Knight ADRC at
Washington University School of Medicine, and consisted of 58 cases and 55 controls. These
were processed to deplete protein, separated by cLC and introduced onto the MS by electrospray
ionization. These specimens came from AD patients and controls matched for gender, age and
APO E4 status, and were devoid of any co-morbidity.
In the comparison of all stages of AD versus controls, 44 significant (p values less than 0.05)
and 25 near significant (p values between 0.05 and 0.10) candidate biomarkers were found using
raw MS data and 38 significant and 21 near significant candidate biomarkers using normalized
data (Chapter 2). Almost all of the biomarker candidates found in the normalized data were
present when using raw data. I looked for gender differences among all of the biomarkers found
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in the first study (Chapter 2). For this purpose, I segregated the data into male cases (n = 29) vs.
male controls (n = 26) and female cases (n = 29) vs. female controls (n = 29). I assessed the
candidate marker’s ability to identify subjects having AD within each gender group. Several of
the markers performed markedly better in one gender than the other. These were considered to be
either male specific or female specific.
Combinations of candidate biomarkers were further modeled to find out if they provided
better diagnostic discrimination. Note that candidates with p-values less than 0.10 were
considered because some of them may provide complementary diagnostic information to other
candidate biomarkers and give better diagnostic discrimination even if they themselves do not
satisfy criteria for statistical significance. Logistic regression analysis and correlation analysis
were performed to model the diagnostic capabilities of the candidates. Specifically, correlation
analysis provided a grouping of biomarkers to identify clusters of candidates that appear to
depict a common pathway and those that are more remotely connected, indicating
complementary differences (potentially different pathways). Finally, a forward-selection method
(leave-one-out approach) was used to build multi-marker diagnostic panels unique to males or to
females. ROC curves were plotted for each gender and AUCs were calculated for the multibiomarker combinations.

4.4. Results

4.4.1 Evaluation of Potential Male and Female Specific Biomarkers and Their Use in Multimarker Panels
I observed that the p values of some of the biomarkers improved markedly (>2 fold better p-
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value) when applied to just men or just women, even with fewer subjects in each gender
comparison set. It is also true that if a specific marker showed improved diagnostic ability in
females, it performed much less well in males (p > 0.15). There were other biomarkers that
performed equivalently for either male or female cases versus controls. These markers showed pvalues in both gender groups that were very similar to their original values, but somewhat less
significant due to a smaller number of subjects in each of the subsets. Statistical analyses
revealed 31 significant or near significant biomarker candidates for women, 16 for men, and 25
additional gender-neutral markers comparing any stage AD to controls. ROC curves were plotted
for single candidate biomarkers.

4.4.2 Evaluation of Biomarkers Specific to Males
Multi-marker combinations were modeled for male-specific biomarkers. There were 10
biomarkers that appeared in 10% or more of all the multi-marker models (See Table 4.1). Multimarker ROC curves were plotted. These provide measures of sensitivity and specificity in
diagnosing AD in men. The best multi-marker panels gave AUCs of 0.820 (See Figure 4.1) and
0.784 (See Figure 4.2). These optimized combinations yielded sensitivities of ~65% with
specificities of ~86%. Dendritic analysis, which relates one marker to another, showed 3-4
distinct groups (See Figure 4.3).

4.4.3 Evaluation of Biomarkers Specific to Females
Similarly, multi-marker combinations were constructed for female-specific biomarkers. The
modeling gave 10 biomarkers that appeared in 10% or more of all female-specific, multi-marker
panels (See Table 4.2). Correlation analysis, dendritic analysis, creation of heat maps and leave-
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Table 4.1. Biomarkers that appeared in 10% of all male specific multi-marker models.
Biomarker Number

Retention Time

Biomarker (m/z

Charge State

(min)

ratio)

(Positive Ion

AUC

Mode)
1

31-38

810.6

1

0.681

2

11-15

971.4

1

0.631

3

21-25

804.6

1

0.620

4

17-25

560.4

1

0.619

5

31-38

1618.2

1

0.613

6

17-25

1170.9

1

0.609

7

17-25

614.4

1

0.558

8

11-15

574.3

1

0.537

9

29-32

804.5

1

0.519

10

16-22

819.5

1

0.413
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Figure 4.1. Multimarker model (ROC curve) for biomarkers 804.6 and 1618.2 for identification of
AD in men.
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Figure 4.2. Multimarker model (ROC curve) for biomarkers 574.3, 1170.0, 810.6 and 804.6 for
identification of AD in men.
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Figure 4.3. Biomarker cluster analysis of 10 best male specific AD biomarkers.
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Table 4.2. Biomarkers that appeared in 10% of all female specific multi-marker models.
Biomarker Number

Retention Time

Biomarker (m/z

Charge State

(min)

ratio)

(Positive Ion

AUC

Mode)
1

22-32

513.3

1

0.706

2

22-32

660.4

1

0.675

3

31-38

1576.2

1

0.662

4

31-38

675.6

1

0.662

5

29-37

1516.2

1

0.632

6

11-15

1107.5

1

0.618

7

11-15

531.3

1

0.580

8

25-34

790.6

1

0.547

9

11-15

515.3

1

0.545

10

8-15

921.4

1

0.545
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one-out analysis were also executed. Multi-marker logistic regression analysis with receiver
operator characteristic (ROC) curves demonstrated combinations that had AUCs of 1.000 (See
Figure 4.4 and 4.5), 0.851 (See Figure 4.6), 0.837 (See Figure 4.7) and 0.828 (See Figure 4.8).
The best of these displayed a sensitivity of 100% with a specificity of 100%. Dendritic analysis
indicated as many as 4 different groups (See Figure 4.9).

4.5 Discussion
Disease prevalence, more so than incidence, provides a better assessment of disease risk. The
older the population, the greater the risk of AD, and women in general live longer than men.
Consequently, the incidence of new cases of AD is greater in women. However, AD also appears
to affect a greater percentage of women than men, and studies suggest AD in women results in
greater and more rapid declines in function (Musicco 2009).
Clinical studies find women to be more prone to develop AD and the progression and
passage of their disease to be different than AD in men (Viña and Lloret 2010, Association 2013).
AD pathology appears to be more extensive in women than in men when matched in other ways
(Barnes, Wilson et al. 2005). All of this suggests differences in AD affecting women versus men.
Consequently, I sought to know if my serum biomarkers would demonstrate gender-related
performance differences. My results found that many biomarkers demonstrated a clearly better
performance in women or in men. This suggests that my biomarkers will likely give very useful
gender specific information in cases of AD.
While this study has primarily focused on diagnostically useful combinations of biomarkers
that are more relevant to one gender, this same approach may be able to provide insights into the
pathological differences of AD in women versus men. By identifying the several molecular
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Figure 4.4. Multimarker model (ROC curve) for biomarkers 675.6, 531.3, 513.3 and 515.3 for
identification of AD in women.
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Figure 4.5. Multimarker model (ROC curve) for biomarkers 531.3, 513.3, 1576.2 and 515.3 for
identification of AD in women.
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Figure 4.6. Multimarker model (ROC curve) for biomarkers 675.6, 1516.2, 921.4 and 790.6 for
identification of AD in women.
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Figure 4.7. Multimarker model (ROC curve) for biomarkers 1107.5, 1516.2, 921.4 and 790.6 for
identification of AD in women.
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Figure 4.8. Multimarker model (ROC curve) for biomarkers 790.6, 1516.2 and 921.4 for
identification of AD in women.
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Figure 4.9. Biomarker cluster analysis of 10 best female specific AD biomarkers.
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species that are altered in women or in men, by looking for connections (as suggested by the
dendritic maps) in these molecules, one may begin to explain clinical findings. However, this
would also require much more detailed information about the patients.
While my results, summarized here, are promising, I realize they are preliminary and require
additional studies to confirm the utility of these biomarkers. Such studies are currently underway
in my lab in a blinded fashion where involved researchers do not know the case or control status
of the subjects from whom the specimens were collected. These studies will take substantial
additional effort to complete. Moreover, there were other candidate biomarkers that were not
considered in the multi-marker panels that could and should be evaluated. Additionally, the
markers would require chemical identification before high-throughput, rapid assays could
possibly be developed. Chemical identification may explain the clustering of compounds seen in
the dendritic maps to know if this represents common pathways or disease processes, or some
other unifying factor.
In conclusion, research studies that have looked at differences in AD prevalence, progression,
and phenotype support differences between men and women. However, gender has not been
considered previously important in diagnostic approaches, but should be considered in both
future clinical and laboratory studies of AD. Very little research has been conducted to
potentially explain such gender differences in AD. Certainly no study of biomarkers for AD has
considered gender, and yet it is entirely possible that development of effective treatments may
differ by gender. My research hypothesis considered gender differences in subjects with AD, and
my data suggest strongly that such differences exist. My data also support gender-specific, serum
biomarkers that improve AD diagnosis in women or in men. My results may provide biomarkers
to detail AD mechanisms involved in the development and progression of AD in both males and
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females. My results also underscore that our serum proteomics approach may be beneficial and
complementary to existing clinical approaches to the diagnosis and, ultimately, treatment of AD
in a gender appropriate approach in males and females.
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CHAPTER 5 – STUDY OF BIOMARKERS DISTINGUISHING DIFFERENT STAGES
OF ALZHEIMER’S DISEASE

5.1 Abstract
Background: Alzheimer’s disease (AD) is typically a slow, progressive disease. The changes
in the brain are thought to start years, perhaps even decades, before the onset of clinical
symptoms. Diagnosis currently relies on cognitive testing and is subjective. Typically, it requires
years to diagnose AD with confidence. For these reasons, AD diagnosis often occurs after the
disease has caused catastrophic and irreversible changes to the brain. Not surprisingly, drug
studies that rely on cognitive testing for AD diagnosis have failed to demonstrate benefit. Early
diagnosis of AD is not currently possible, and yet is paramount to the development of treatment
options and to better understand the biochemical pathways that lead to AD. In an effort to find
markers for early stage AD, we used a serum proteomics approach that allows us to evaluate
thousands of low-molecular weight biomolecules in serum as potential biomarkers.
Methods: Serum samples from 19 individuals with moderate AD, CDR of 2.0, and 11
individuals with a very mild or mild clinical AD, CDR of 0.5 or 1.0, were previously analyzed
by MS as part of an initial study to discover novel AD biomarkers for any stage AD. In turn this
study focused on efforts to find AD biomarkers that differed between patients having mild AD
compared with patients having moderately severe AD. Data were organized by CDR status and
all peaks were overlaid and reviewed for possible quantitative differences. Initially, peak heights
for peaks that appeared quantitatively different were obtained, combined by group and assessed
statistically using the Student’s t-test. Multi-marker panels that can diagnose AD among patients
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at different stages of the disease were also modeled.
Results: We found 44 significant and near significant biomarkers that were quantitatively
different between mild and moderately severe AD. The best combination resulted in an ROC
curve having an AUC of 0.892 and providing a sensitivity and specificity ≥90%.
Conclusion: The serum proteomics approach appears able to find serum biomarkers that are
different at different stages of Alzheimer’s disease. This can potentially not only help in
diagnosis, but also give clues about the biochemical pathways involved in the disease.

5.2 Introduction

5.2.1 Onset of Alzheimer’s Disease
AD is an immedicable and relentless brain disease. It is known to steadily diminish the
ability to remember and think, and to perform simple daily activities/chores. Despite its
prevalence and devastating consequences, we do not understand precisely how the disease
process starts. Current research indicates that detrimental changes in the brain begin at least a
decade before the onset of dementia and other clinical symptoms (Foundation).

5.2.2 Review of Current Biomarkers for Early Diagnosis
There have been attempts at finding early stage biomarkers. These are reviewed in the
following paragraphs.

5.2.2.1 CSF biomarkers
Currently, increased CSF tTau or pTau protein levels and decreased Aβ-42 levels are the
116

only biomarkers with demonstrated sensitivity and specificity to differentiate between AD and
other dementias in their early stages (Rösler N 2002, Sunderland, Linker et al. 2003, Galasko
2005, Wiltfang, Lewczuk et al. 2005, Hampel and Buerger 2006, Hansson, Zetterberg et al. 2006,
Parnetti, Lanari et al. 2006, Bailey 2007, Finehout, Franck et al. 2007, Engelborghs, De Vreese
et al. 2008). They are possible indicators of disease severity and may correlate with increasing
numbers of AD symptoms (Hampel, Mitchell et al. 2004, Lewczuk, Esselmann et al. 2004,
Vanderstichele, De Meyer et al. 2005, Jellinger 2006, Stefani, Martorana et al. 2006, Wallin,
Blennow et al. 2006, Speth, Sindic et al. 2007). Increased values of tTau CSF concentrations
were documented between early and advanced stages of AD (Andersson, Blennow et al. 2008).
However, changes in soluble Aβ-42 have not been found to parallel the degree of cognitive
decline (Stefani, Martorana et al. 2006). In one study, the Aβ-42/40 ratio was associated with
changes in pTau levels in patients with low and high CSF Aβ-40 levels, but was not associated
with Aβ-42 levels alone (Wiltfang, Esselmann et al. 2007).
Studies have shown that a marked increase of beta-secretase 1(BACE 1) CSF levels and
activity were correlated with mild cognitive impairment (MCI). Also, increases in other
neuroimmune markers appear to precede clinically severe AD in some studies (Gruden,
Davidova et al. 2007, Zhong, Ewers et al. 2007).
Longitudinal cohort studies done recently found increased levels of CSF Aβ-42 and tTau (but
not pTau phosphorylated at threonine 181) in a group of patients in a memory clinic with similar
levels in all diagnostic groups. In that study, the cross-sectional variation between diagnostic
groups was substantially greater than the longitudinal differences observed within individuals.
This demonstrates that these markers were not biomarkers of disease advancement (Bouwman,
van der Flier et al. 2007). A problem has been that most studies evaluating these biomarkers have
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used clinical diagnoses alone rather than including pathological changes (Jellinger, Janetzky et al.
2008). This may or may not explain the general poor performance of these biomarkers in staging
AD.

5.2.2.2 Plasma biomarkers
In plasma, total amyloid precursor protein or Aβ-42 was found increased in cases of familial
AD (Schupf, Patel et al. 2001, Ertekin-Taner, Younkin et al. 2008), but has failed as diagnostic
biomarkers in cross-sectional studies of sporadic AD (Tamaoka, Fukushima et al. 1996, Mehta,
Pirttilä et al. 2000, Vanderstichele, Kerschaver et al. 2000, Fukumoto, Tennis et al. 2003, Assini,
Cammarata et al. 2004, Crystal and Davies 2008, Ertekin-Taner, Younkin et al. 2008). In some
studies, higher levels of Aβ-42, decreased levels of Aβ-40 and a reduced Aβ-42/Aβ-40 ratio have
been found in the plasma of cases compared with controls and levels changed with disease
progression from cognitively normal to MCI to AD (van Oijen, Hofman et al. 2006, GraffRadford, Crook et al. 2007, Sundelöf, Giedraitis et al. 2008). In direct contradiction, other
studies concluded that lower levels of Aβ-42 plasma might indicate the transition from MCI to
AD (Song, Mook-Jung et al. 2007). Perhaps owing to high intra- or inter-personal variability of
serum and plasma Aβ levels (Abdullah, Paris et al. 2007), plasma levels of Aβ-40 and Aβ-42
have failed to correlate with histologically or biochemically assessed amyloid plaques in the
brain (Freeman, Raju et al. 2007). Currently, it is accepted that plasma Aβ-42 levels alone are not
reliable biomarkers for MCI and AD (Mehta, Pirttilä et al. 2000, Brettschneider, Morgenthaler et
al. 2005, Blasko, Jellinger et al. 2008).
Inflammatory molecules found in blood, such as C reactive protein (CRP), interleukin-6, and
others, have been proposed as biomarkers for vascular dementia (Bibl, Esselmann et al. 2007,
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Ravaglia, Forti et al. 2007) or appear to be increased prior to the clinical onset of symptoms in
both AD and vascular dementia (Engelhart, Geerlings et al. 2004). However, these markers are
not specific for AD, but are increased in multiple diseases. Plasma Aβ is a risk factor for AD in
several longitudinal cohort studies with changes in Aβ levels observed 5–20 years before the
patient dies (Mayeux, Honig et al. 2003, van Oijen, Hofman et al. 2006).
Proteomics approaches used on plasma have revealed increased concentrations of α-1antitrypsin and apolipoprotein J in individuals with AD (Liao, Yu et al. 2007). Plasma
homocysteine has been shown to be directly related to Aβ-40 levels, while the association with
Aβ-42 was not significant, suggesting that homocysteine is related to aging but not specifically
to AD, although it may interact to affect AD risk and cognition in Parkinson’s disease (Mayeux,
Honig et al. 2003, Irizarry, Gurol et al. 2005, Luchsinger, Tang et al. 2007). Thus, the
ineffectiveness of Aβ as an AD marker in plasma/serum as well as its non-specificity and the
absence of other AD markers currently require further work to find diagnostic serum biomarkers
for AD, and especially biomarkers for early stage AD (Jellinger, Janetzky et al. 2008).

5.2.2.3 Platelet biomarkers
Studies of platelets in AD suggest that changes in amyloid precursor protein predict
conversion of MCI into dementia (Borroni, Colciaghi et al. 2003, Tang, Hynan et al. 2006).
Other platelet studies have found an association of membrane fluidity with cognitive decline
(Zainaghi, Forlenza et al. 2007). Higher BACE-1 activity in platelets from AD patients compared
with controls (Johnston, Liu et al. 2008), and an increase in monoamine oxidase B expression
have been reported in the platelets and brain tissue of demented individuals having AD or PD.
This has been replicated by others (Adolfsson, Gottfries et al. 1980, Jarman, Glover et al. 1993,
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Jellinger, Janetzky et al. 2008). Recently, increased platelet phospholipase A2 activity has been
reported in patients with AD, vascular dementia or ischemic stroke (Krzystanek, Krzystanek et al.
2007, Jellinger, Janetzky et al. 2008). Although some of these may have appeared changed in
response to disease, they lack specificity.

5.2.2.4 Structural biomarkers
The usefulness of magnetic resonance imaging (Blasko, Jellinger et al. 2008) in observing
structural changes in the diagnosis and staging of AD has been reviewed (Barnes, Foster et al.
2007, Jellinger, Janetzky et al. 2008, Vemuri, Gunter et al. 2008). Medial temporal lobe atrophy
(MTA) as assessed by MRI is sensitive to primary degenerative hippocampal atrophy in elderly
seniors. However, a moderate MTA score has not been linked with dementia (Barkhof,
Polvikoski et al. 2007), but has been linked to MCI (Mevel, Desgranges et al. 2007).
Nevertheless, these changes are not specific for AD. In contrast, the amount of increased
positron emission tomography (PET) measured amyloid-binding ligand (11C) PIB uptake in the
brain of subjects with possible MCI/mild AD appears indicative of early AD (Klunk, Engler et al.
2004, Kemppainen, Aalto et al. 2007, Rowe, Ng et al. 2007, Jellinger, Janetzky et al. 2008).
Examination of CBF-SPECT, CMRgl-PET (glucose metabolism), proton spectroscopy (H-1
MRS), high-field strength functional MRI, voxel-based morphometry, increased activation of the
mediobasal temporal lobe detected by fMRI, (R)-[(11)C]PK11195 PET to detect microglia,
combined PiB imaging and structural MRI studies appear to be predictive for conversion of MCI
into early AD (Apostolova, Steiner et al. 2007, Bracco, Bessi et al. 2007, Caroli, Testa et al.
2007, Hämäläinen, Tervo et al. 2007, Huang, Eidelberg et al. 2007, Kantarci, Weigand et al.
2007, Kircher, Weis et al. 2007, Kropholler, Boellaard et al. 2007, Petrella, Wang et al. 2007,
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Rami, Gomez-Anson et al. 2007, Jack, Lowe et al. 2008, Prince, Woo et al. 2008). Similarly
accelerated rates of hippocampal atrophy and ApoE ɛ4 prevalence (Van de Pol, van Der Flier et
al. 2007), FDG-PET (Samuraki, Matsunari et al. 2007), detection of subcortical hyperintensities
(Debette, Bombois et al. 2007, Huang, Friedland et al. 2007, Smith, Egorova et al. 2008) and
MRI patterns of grey matter atrophy (Whitwell, Shiung et al. 2008) are also indicative of AD
type pathology and conversion of MCI into early AD. Some argue that relatively normal
metabolism of glucose in the presence of high frontal amyloid load suggests that amyloid plaque
formation may not be directly responsible for neuronal dysfunction in this disorder (Edison,
Archer et al. 2007). Cortical and hippocampal atrophy in aging and dementia are complicated by
the many processes acting on brain structures that can mediate cognitive deterioration (Jagust,
Zheng et al. 2008).

5.2.2.5 Alzheimer Associated protein (ALZAS)
Alzheimer Associated protein is an Aβ protein expressed in aging patients with the likely
diagnosis of AD. The gene for the protein was discovered on chromosome 21 within the APP
gene region. This protein, has a 79 amino acid sequence and contains the Aβ-42 fragment, the
amyloid protein transmembrane signal and a unique 12 amino acid c-terminal, which is absent in
all known allelic forms of the amyloid precursor protein (Kienzl, Jellinger et al. 2002, Kienzl,
Jellinger et al. 2006). Reverse transcription PCR studies revealed that the mRNA expression of
this protein was found in cortical and hippocampal regions of the brain and in lymphocytes of
older individuals with AD (Kienzl, Jellinger et al. 2002, Kienzl, Jellinger et al. 2006, Kienzl,
Jellinger et al. 2007, Jellinger, Janetzky et al. 2008).
In summary, despite all of these efforts to identify biochemical biomarkers or radiologic
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measured changes in brain architecture, there are no clinically approved early stage biomarkers
for AD. Moreover, the great majority of studies focusing on AD serum biomarkers have
attempted to demonstrate differences in the Aβ or tau proteins without success. My approach is
completely novel and has ability to find biomarkers not previously considered.

5.2.3 Alzheimer’s Disease is Multifactorial
Recently, Iqbal et al. proposed that AD is a heterogeneous disease (Iqbal and Grundke-Iqbal
2010). They suggested that AD is caused by a number of factors including multiple genetic,
environmental, or lifestyle factors, or from a combination of all three. Less than 1% of AD cases
are a result of genetic mutations. Known mutations include transmembrane proteins like amyloid
precursor protein, presenilin 1, and presenilin 2 (Bird 2008). Sporadic AD that is not associated
with any known genetic mutations represents greater than 99% of all AD. This classification has
been further subdivided into AELO (AD cases with low Aβ1–42, high incidence of APOE ɛ4, and
late onset), ATEO (AD cases with low Aβ1–42, high tau, and early onset), LEBALO (AD cases
with high incidence of Lewy bodies, low Aβ1–42, and late onset), HARO (AD with high Aβ1–42,
and recent onset) and ATURO (AD with low Aβ1–42, high tau, high ubiquitin, and recent onset),
each presumably due to several different etiopathogenic mechanisms as shown in Figure 5.1.
Also, if an individual carries one or two copies of the APOE ɛ4 allele instead of APOE ɛ2
or APOE ɛ3, the risk for the development of sporadic AD is increased by many fold (Corder,
Saunders et al. 1993).
Even though many plaques and neurofibrillary tangles are observed in AD pathology, the two
lesions occur in different proportions among different cases of AD. This is the basis for
separating the plaque- and tangle-dominant AD subgroups (Katzman, Terry et al. 1988,
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Figure 5.1. Possible subgroups of Alzheimer's disease based on the risk factors. Reprinted from
(Iqbal and Grundke-Iqbal 2010) with permission. ©Elsevier, 2010.
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Jellinger and Attems 2007). The Amyloid Cascade Hypothesis (Hardy and Higgins 1992, Hardy
and Selkoe 2002) states that the main cause of neurofibrillary degradation and dementia is the βamyloid precursor protein (β APP) and its fragment, Aβ. However, the absence of any
correlation between the number of plaques and the number of tangles in AD, the existence of
various phenotypes of Aβ plaques, together with the lack of neurofibrillary degeneration in
normal elderly humans is contradictory to the hypothesis. On the other hand, the hypothesis is
reinforced by the findings of a study that showed that introduction of Aβ1–42 in P301L tau
transgenic mice (Götz, Chen et al. 2001) and P301L tau transgenic mice with APPSWE (APP with
Swedish mutation) (Lewis, McGowan et al. 2000) worsened tau neurofibrillary pathology. This
worsening of tau pathology may be attributed to activation of the stress-activated protein kinases,
known to phosphorylate tau at the various proline-directed sites. However, none of these tau
mutations have been observed in actual AD patients. Moreover, abundant Aβ plaques have been
observed in the neocortex of healthy, aging people as well as abundant Aβ content found in
genetic cerebral hemorrhage with amyloidosis, but without any neurofibrillary pathology present
(Levy, Carman et al. 1990, Dickson, Crystal et al. 1992). All of this makes the Amyloid Cascade
Hypothesis untenable for AD and its attendant changes in the human brain. Thus, we do not as
yet understand the origins of neurofibrillary tangles and Aβ plaques. This situation suggests
strongly the need for more global evaluation of molecules in AD that might be useful as
biomarkers and that additionally might shed light on the progressive mechanisms leading to last
stage AD.

5.2.4 Unknown Mechanisms Involved
While the cause of AD is unknown, the genetic and pathological studies done over the past
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20 years still suggest that aggregation of amyloid-beta contributes to the pathogenesis of AD
(Hardy and Selkoe 2002). Aβ plaque formation is likely to contribute to several later biochemical
changes including neuroinflammation, synaptic dysfunction, tauopathy, and apoptotic events
leading to cell death. This concept is called “amyloid cascade hypothesis.” Notwithstanding this
theory, β-amyloidosis and Aβ plaque burden do not correlate with the onset or level of cognitive
decline in the transition from MCI to dementia to later stages of AD. This clearly implies that
other factors are mediating or contributing to the advancement of the disease. New research data
show that approximately 30% of all individuals over the age of 75 have the characteristic
neuropathological features of AD when their brains were studied by autopsy without functional
evidence of AD. These individuals were considered clinically normal at the time of death. Hence,
significant AD lesions evident in these individuals’ brains without disease symptoms could be
interpreted as no direct causal link between Aβ pathology and AD cognitive function, or to the
possibility of yet-to-be-specified protective mechanisms that preserve cognitive function in the
face of pathologic processes (Iacono, O’Brien et al. 2008, Iacono, Markesbery et al. 2009,
Alkadhi and Eriksen 2011, Driscoll and Troncoso 2011). To identify such compensating
mechanisms, many approaches may be needed, including proteomic studies that might reveal
novel pathways. Such approaches, especially comparing changes as a function of AD disease
stage can potentially map out the one or more mechanisms involved in this disease. While
identifying these potentially new pathways was not a direct goal of our studies, demonstrating
differences in the complement of peptides and proteins present in serum at different stages of AD
progression opens the door to that possibility.
5.3 Materials and Methods
This study relied on the same set of specimens as described in Chapter 2 and included sera
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from 58 cases with AD and sera from 55 non-demented controls obtained from Knight ADRC,
Washington University School of Medicine. These were processed as previously described and
analyzed by cLC-ESI-MS/MS. Of these, samples of 19 cases with a moderate clinical dementia
rating of 2.0 and 11 cases with very mild or mild clinical dementia ratings of 0.5 (n = 7) or 1.0 (n
= 4) were compared. All peaks were reviewed in a de novo effort to locate biomolecules that
were differentially expressed at different stages of AD. All aspects of data analysis, statistical
analysis and testing of multi-marker sets to find AD stage-specific serum biomarkers in this
study were performed again on these data sets using the procedures outlined in Chapter 2 in the
Methods section.

5.4 Results

5.4.1 Discovery of Candidate Serum Biomarkers for Early Stage AD
On examining raw, un-normalized MS data, 4 statistically significant AD stage dependent
serum biomarkers were found comparing patients having very mild and mild stage AD (CDR =
0.5, 1.0) with patients having later stage, moderate AD (CDR = 2.0). Additionally, 16 nearsignificant biomarkers that had p-values between 0.05 and 0.10 were found. Upon log
normalizing the mass spectral data for each candidate to an internal molecular species from the
same time window (that was equivalently distributed between cases and controls), I found 13
significantly different serum biomarkers along with 19 candidates that were near significant (p =
0.05 to < 0.10). When un-normalized or normalized data were combined, 20 unique potential
biomarkers were found (p values < 0.05) with another 24 near-significant biomarkers (p values
between 0.05 and 0.10) (See Table 5.1). These were further statistically assessed by receiver
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operator characteristic curve analysis applied to all 44 candidate biomarkers. Some of the AD
biomarkers were higher in cases and others in controls.

5.4.2 Assessment of Diagnostic Similarities between Biomarkers
First, all the data was clustered and it was observed that the markers could distinguish mild
stage AD versus moderate stage AD very well. Second, correlation analyses of all biomarker
pairs were applied to all of the biomarkers. During the process, a heatmap, clustering dendogram
and correlation matrix that identified biomarkers that were closely correlated were produced. The
markers that closely correlated provided similar diagnostic information, while those that showed
little correlation provided added and complementary diagnostic information.

5.4.3 Evaluation of the Biomarkers in Multi-marker Panels
Further, the combinations of these serum biomarkers were tested to see if they would provide
better diagnostic discrimination between different stages of AD. Again, the forward selection
approach was used to construct multi-biomarker models. Significant as well as near significant
biomarkers were considered, owing to the fact that near significant biomarkers might potentially
add complementary diagnostic information on subjects with earlier stage AD as opposed to the
ones with more severe AD. Log normalized data was used to build multi-marker panels. Multibiomarker panels were created by including statistically different or near different candidates one
by one until a combination of the panel yielded the best AUC possible. There were 13
biomarkers that appeared in 9% or more of all the multi-marker models (See Table 5.2). These
were considered to be more robust and likely more valuable.
Additional statistical analyses centered on the 13 biomarkers, on which again a forward
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Table 5.1. List of 20 significant (p value < 0.05) and 24 near-significant (p value between
0.05 and 0.1) biomarkers when raw and normalized data were considered. [Letters in the
brackets indicate position of the biomarker within the time range (A = aligned, L = left, R =
right, RO = right, outside)]. These are indicated, in cases, where there are multiple marker
peaks with the same m/z ratio in the same time window.]
Peptide
number

Approximate
elution time
window (min)

m/z of
biomarker

Charge
(Positive
ion
mode)

p value for
log of ratio
of potential
biomarker
to
reference
biomarker
0.0339

p value for
unnormalized
potential
biomarker

2

p value for
ratio of
potential
biomarker
to
reference
biomarker
0.1102

1

8-15

744.35

2

8-15

808.80

2

0.0755

0.0699

0.1483

3

8-15

675.80

2

0.0926

0.0813

0.2356

4

11-17

1446.50

1

0.1910

0.0637

0.0688

5

11-17

1073.46

1

0.0585

0.0790

0.2467

6

11-17

1307.50

1

0.0217

0.0485

0.1362

7

11-17

1379.50

1

0.0190

0.0224

0.1064

8

13-19

566.30

1

0.4779

0.4849

0.0978

9

13-19

1238.50

1

0.0986

0.1242

0.3367

10

13-19

603.30

1

0.0716

0.1606

0.3844

11

13-19

589.30

1

0.2988

0.3484

0.0480

12

13-19

571.36

1

0.0355

0.0487

0.2834

13

13-19

593.35

1

0.0217

0.0463

0.2766

14

13-19

1260.52

1

0.0118

0.0541

0.3631

15

13-19

764.50

1

0.0113

0.0504

0.3281

16

13-19

620.30

2

0.1220

0.0366

0.0938

17

16-22

552.30

1

0.0444

0.0070

0.0517

18

17-25

536.30

1

0.0975

0.1494

0.1996

19

17-25

538.30

1

0.0776

0.1695

0.1882

20

17-25

529.30

1

0.1328

0.0839

0.0784

21

17-25

558.3(L)

1

0.0801

0.0637

0.1830

22

17-25

534.30

1

0.0480

0.0672

0.0798
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0.2475

23

17-25

518.30

1

0.0147

0.0270

0.0758

24

17-25

558.3(R)

1

0.0280

0.0366

0.2001

25

20-27

531.39(R)

1

0.1121

0.1009

0.0662

26

20-27

504.30

1

0.1104

0.0916

0.1654

27

20-27

583.35

1

0.0777

0.1625

0.0847

28

20-27

546.40

1

0.0644

0.0963

0.2014

29

20-27

531.39(A)

1

0.1195

0.0608

0.0404

30

20-27

1067.70

1

0.0317

0.0314

0.0716

31

20-27

1091.70

1

0.0195

0.0224

0.0644

32

22-32

692.50

1

0.1777

0.2178

0.0904

33

22-32

513.35

1

0.1064

0.1824

0.0623

34

22-32

1019.70

1

0.0995

0.1317

0.1400

35

22-32

1196.80

1

0.0972

0.1366

0.3047

36

22-32

652.40

1

0.0856

0.0704

0.0991

37

22-32

567.30

1

0.0688

0.0558

0.1340

38

22-32

662.40

1

0.0557

0.0546

0.0685

39

22-32

1123.70

1

0.0442

0.0306

0.1575

40

22-32

617.4(R)

1

0.0417

0.0681

0.0332

41

22-32

617.4(RO)

1

0.0428

0.0716

0.0179

42

27-36

922.60

1

0.0796

0.0762

0.3618

43

27-36

924.60

1

0.0096

0.0117

0.2433

44

29-37

766.60

1

0.0737

0.0788

0.0946
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selection approach was repeated with complementary correlation analysis. This resulted in
dendritic analysis and heat maps. ROC curves were plotted to study the performance of panels of
these biomarkers in identifying early stage AD. The best combinations using two or more of the
13 biomarkers provided AUCs of 0.892 and 0.882 (See Figure 5.2 and 5.3). The best
combination resulted in an ROC curve with an AUC of 0.892 and provided a sensitivity and
specificity ≥90%, while the second best combination with an AUC of 0.882 provided a
sensitivity of 100% at a specificity of ~75%. There were 6 multi-marker models that had an
AUC of greater than 0.80 and another 2 with an AUC of ~0.80.

5.4.4. Cluster Analysis
Cluster analysis was done on the subset of 13 biomarkers. The dendritic analysis suggested
that there might be 4-5 groups (See Figure 5.4).

5.5 Discussion
Chemical diagnosis of AD is not currently possible. Biochemical staging of AD using serum
biomarkers, however important, likewise does not exist. My hypothesis was that a more global,
proteomics approach could be successfully applied to serum to find AD disease stage specific
differences in the molecular expression levels in serum. My results suggest strongly that the
approach is feasible and the hypothesis correct. Comparison of very mild/mild stage AD (CDR =
0.5, 1.0) samples to moderate stage AD (CDR = 2.0) provided 44 candidate biomarkers that
looked promising. The best multi-marker combination was able to diagnose early stage AD with
~90% sensitivity and >90% specificity. Validation and identification of the biomarkers that
appear to be diagnostically useful will be performed in the future.
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Table 5.2. Set of 13 biomarkers that appeared in 9% or more of all the multi-marker
models.
Elution
time
window
(min)

m/z of
biomarker

Charge
(Positive
ion
mode)

p value for log
of ratio of
potential
biomarker to
reference
biomarker
0.0339

p value for
unnormalized
potential biomarker

2

p value for
ratio of
potential
biomarker
to reference
biomarker
0.1102

1

8-15

744.35

2

8-15

808.80

2

0.0755

0.0699

0.1483

3

11-17

1073.46

1

0.0585

0.0790

0.2467

4

13-19

571.36

1

0.0355

0.0487

0.2834

5

16-22

552.30

1

0.0444

0.0070

0.0517

6

20-27

504.30

1

0.1104

0.0916

0.1654

7

20-27

1067.70

1

0.0317

0.0314

0.0716

8

22-32

692.50

1

0.1777

0.2178

0.0904

9

22-32

662.40

1

0.0557

0.0546

0.0685

10

22-32

617.4(RO)

1

0.0428

0.0716

0.0179

11

27-36

922.60

1

0.0796

0.0762

0.3618

12

27-36

924.60

1

0.0096

0.0117

0.2433

13

29-37

766.60

1

0.0737

0.0788

0.0946
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Figure 5.2. Multimarker model (ROC curve) for biomarkers 552.3, 744.4 and 662.4.
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Figure 5.3. Multimarker model (ROC curve) for biomarkers 808.8, 552.3, and 571.4.
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Figure 5.4. Biomarker cluster analysis of 13 AD biomarkers subset.
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Studies conducted to find diagnostic early stage biomarkers heavily rely on the quality and
number of samples available for analysis. My samples were obtained from the Knight ADRC,
Washington University School of Medicine. They are known to have stringent criteria for AD
diagnosis and staging. The cases and controls were age and gender matched along with the
fraction of subjects with the APOE e4 allele. Patients having co-morbidities such as diabetes
were not included in the study. This helps increase the likelihood of higher true positive
diagnostic rate among the individuals with early stage AD as opposed to other diseases or
dementias.
We had fewer samples for comparison between different stages. However, this method has
worked very well in all the studies described in the previous chapters in this dissertation. The
thoroughness and complexity of the serum proteomic approach has enabled us to observe greater
than 8000 spectral peaks and obtain promising results.
Normalized data were used for initial biostatistical analyses to remove any variability if
present from run to run.
Panels of biomarkers were developed using a ‘leave one out’ model to provide several panels
of markers that had sensitivities and specificities greater than those of individual biomarkers. All
further analyses were limited to the 13 biomarkers that appeared in more than 9% of all the
models. Using just these 13 candidate markers, I still had 8 panels with acceptable AUCs of
≥0.80. Cluster analysis suggested 4-5 different groups of related biomarkers. The markers with
strong correlation might represent a common parent compound or represent similarities in
biological staging, processes or pathways.
In conclusion, the serum proteomic approach used here was able to find novel candidate
biomarkers for staging mild AD compared with moderate AD.
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CHAPTER 6 - CONCLUDING REMARKS

6.1 Summary
In conclusion, my research can be summarized as follows.
A sizeable initial study of serum from 58 AD cases and 55 age and gender-matched controls
was carried out using a novel serum proteomics approach, focusing on lower molecular weight
species. This yielded 38 statistically significant biomarkers and another 21 near significant
biomarkers. Combinations of these provided panels of markers that diagnose AD correctly ~90%
of the time. Currently there are no approved diagnostic biomarkers for AD in blood or
cerebrospinal fluid.
In that same data set, I found several biomarkers that were significantly different only in
women or only in men. While there is evidence for gender differences in AD, my findings have
implications for diagnosis, disease mechanism(s) and the development of effective therapeutics.
Analyzing data from the initial AD study, 44 additional significant and near significant
candidate serum biomarkers were found that were quantitatively different between mild and
severe AD.
Subsequently, a follow up, blinded validation study with 125 additional, previously unstudied
subjects was performed, and data were extracted for the 13 most promising diagnostic
biomarkers from the initial study. Of these, 4 of the original markers have replicated successfully,
and I have identified these as completely as is currently analytically possible. Sets of these
provide accurate diagnosis of ~83% of very early AD with a specificity of ~78%.
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6.2 Limitations
As with every research study, potential pitfalls exist. These are detailed as follows.
When I began my discovery study to find serum biomarkers for Alzheimer’s disease using a
proteomics approach, I anticipated finding primarily peptide biomarkers. However, I found that
the latter half of our useful chromatographic region contained predominantly lipid molecules. Of
these, most detected in the positive ion mode were phosphatidylcholines and oxidation products
of phosphocholines, because most other lipid classes are not easily positively ionized without
forming adducts. Another possible problem is that lipids are very sticky using reversed phase
chromatographic phases and may, if one is not careful, get carried over into the next run. For this
reason, I conducted a wash run with high organic phase followed by adequate equilibration time
after every sample during the replication study, but not during the initial study.
Lipids with few exceptions are stable under the conditions used here and this would make
them attractive as biomarkers. Oxidized lipids are often an indication of a diseased state, and
they point to mechanisms involved in a disease. However, my procedure used a bicinchoninic
acid (BCA) protein assay to quantitate 5 μg of apparent protein in each sample to be loaded on
the cLC-MS/MS system. While this might have quantitated the proteins correctly, I am unsure if
lipid loading was quantitatively accurate by this method. A possible downside could be that too
little specimen was loaded and potential lipid biomarkers might be lost. As is clear from a review
of lipidomics research, there are no assays used to quantitate lipids. Most of the lipidomics
researchers just use equal volumes for quantitating their samples. These issues would lead to
greater random variability and decrease statistical significance, reducing the number of
candidates. The ability for results to be replicated then suggests that differences are real and not
artifacts of processing. My research has replicated 3 lipid biomarkers and their p-values were

137

very significant.
Another challenge is that lipid identification is not nearly as straightforward as
protein/peptide identification for which we have search engines, easily recognizable fragments
representing b- and y-series ions, etc. I have used the Lipidmaps database and found some
possible matches for lipid molecules. However, this database relates to accurate masses and does
not provide fragmentation data or allow for fragmentation data to be matched to archived MS
data. Neither does it contain oxidation products of lipids in its database. Smaller amounts of
serum samples and the exceptionally low concentrations present in those specimens rule out
options to characterize them as organic chemists do. Research on lipids is in its infancy and is
limited compared to proteins, but occasionally answers can be found by surveying the literature.
Even so, this does not always guarantee an exact identity. It is practically impossible to locate the
positions of double bonds. If available, lipid standards of expected molecules may be bought and
fragmented to see if MS data match the fragmentation spectrum of the biomarker of interest. The
selection of commercially available lipids is very limited and contains no oxidized species.
Experience tells me that there should be hydrophobic peptides eluting in some hydrophobic
regions where lipids are seen. I have observed this to be true. However, these peptide biomarkers
undergo ion suppression due to the presence of more prominent lipid peaks. This reduces the
likelihood of finding many hydrophobic peptide biomarkers. I have discovered a charge state +5
peptide biomarker in the hydrophobic region that was highly significant in the validation study.
It has isotopic peaks overlapping with a validated lipid biomarker in that region. My efforts to
manually analyze all of my data, although very time consuming, makes this possible. Hence, I
continued to use this approach in the absence of software that can work with the complexity of
our data.
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Another thing I have noticed is the presence of lipid dimers in our MS2 spectra data. These
are potentially formed in the ESI step. Some of these performed well enough to be considered
candidates in the initial study. However, given their potential artifactual production, it is not
surprising that they did not replicate well. Even so, they are not useful biomarkers if they are not
formed inside the body.
Peak overlaps are common for complex biological samples. Using high-resolution
instruments helps but does not completely eliminate this problem.
Use of several different software programs to compare group data have been tried and have
been disappointing. Manual analysis with all of its problems has frequently helped me find
biomarkers that were missed by automated software programs. Each of my files, which were
from 1 to 5 GB in size for 2 min windows, limited comparison of 60 cases and 60 controls. My
method demanded much time, manual power and high speed computing resources. Such an
approach prolonged the analysis time substantially.
I overlaid MS spectra during the initial study to visually look for peaks that appeared
quantitatively different between cases and controls. This might not be the best procedure to look
for potential biomarkers, given the desire to compare normalized samples. Normalization of the
MS data is intended to reduce variability due to sample processing, sample loading, ionization
inefficiencies and changes in instrument sensitivity. Normalization then should improve
statistical differences, but this did not always occur, suggesting that the endogenous reference
marker was not adequate or appropriate for that specific biomarker candidate. A significant
concern was that I might have lost good biomarkers due to this technique, both without
normalization and with normalization. Unfortunately, finding reliable reference peaks was
difficult, especially for lipids, did not improve p-values or improved them negligibly and was not
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attempted in the replication study.
Some of the issues with reference peaks included peaks too large or too small, distant in their
elution time, markedly different in m/z value, having complicated isotope envelopes, uncertainty
as to their quantitative neutrality between cases and controls, their absence in some specimens
and more. I have strived to find the best reference markers possible.
Another concern in using internal reference markers was that a lipid molecule was used to
normalize a peptide biomarker. While this is not ideal, I have attempted, where possible, to make
reference and marker chemically similar.
Ideally, I could use a range of m/z values that takes in just one monoisotopic peak when
recording extracted ion chromatogram intensities. However, this usually led to very low
extracted ion chromatogram peak intensities for several biomarkers, so low that it could affect
the accuracy due to low signal to noise. I overcame this problem by using slightly larger ranges
such that they covered two isotopic peaks. This came with a potential complication of its own,
risking the quantitation of neighboring peaks having some level of overlap with our molecule of
interest.
While there are no FDA approved drugs given to AD patients, many of the subjects may be
on some type of medication. Subjects had no major intercurrent diseases, but I cannot rule out
some medication use among subjects, and this could modify the quantities of biomarkers.
Certainly, the biomarkers I have found are not drugs or drug metabolites. Availability of more
patient data would be reassuring.
I have studied only a cross section of people representative of AD and matched, nondemented controls. However, in a larger cohort or individuals from another part of the world,
there is always a possibility of these biomarkers working differently. Remember, there is
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evidence that AD is not uniform in its cause, presentation or progression, leaving open the
possibility that there may be environmental factors. Longitudinal studies, while currently almost
impossible to carry out, would be very important.
Also, patients with AD have several other diseases since they are typically old. Other
diseases may affect levels of AD biomarkers found in these studies. My study used cases and
controls without co-morbidities, and assumed that the levels will continue to be different in
individuals with AD and comorbidities.
In my initial sample set, I had several samples with CDR 2.0 and 3.0, which are
representative of severe stage disease, and very few with CDR 0.5 and 1.0 that are indicative of
mild stage AD. In the replication study, I had many more very mild and mild AD subjects and no
CDR 3 subjects. All the stages were studied in the initial set. This might have reduced replication
of some biomarkers.

6.3 Future Research
This was and continues to be a vast project. Although I finished preliminary studies and
assessed validation of the 13 most promising biomarkers found in the initial study, there is much
more that can be done. A few possible future research studies are as follows:
The validation study should be extended to the 38 statistically significant biomarkers and the
additional 21 near significant biomarkers found in the initial study. Since two of the biomarkers,
1568.2 and 1618.2, among the 13 were lipid dimers and two others, 708.3 and 660.4, could not
be quantified with confidence, I have really studied only a small portion of the potential
biomarkers. The fact that 804.55 found between 39.5-41.5 min was validated successfully, but
did not belong to the list of 13 biomarkers, proves that more useful results can be obtained by
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evaluating the other biomarkers from the initial study. Further biostatistics involving regression
and correlation studies could be added. Multi-marker panels should be reconsidered after
studying all of the biomarkers from the initial study.
Finding more biomarkers among the currently unevaluated candidates found in the initial
study would then require more chemical characterization and identification studies. Hence, more
fragmentation studies are anticipated in the future. Additionally, I don't have absolute identities
of our oxidized biomarkers. These could be investigated further until complete identities are
obtained.
Data can be further statistically evaluated to build multi-marker panels for comparisons
between very mild and mild AD (CDR = 0.5, 1.0) and moderate AD (CDR = 2.0) for biomarkers
found in the initial study when these stages were compared (see Chapter 5).
Further, biomarkers that were found while studying different stages have not been validated.
A study could be undertaken to validate and identify these.
Also, biomarkers that were male and female specific have not yet been validated. Replication
studies with identification of these in the same data set that I used can be done in the future as
well. Also, the validated biomarkers have not been tested as a function of gender.
It would be interesting to obtain serial specimens from AD patients and look for biomarkers
that predict those who have a slow time course for their disease and those that demonstrate rapid
decline in their cognitive function. Such markers would be valuable in designing drug studies.
Once all validation and identification studies are done, disease mechanisms can be
investigated.
For diagnostic purposes, if possible, there could be studies to build more quantitative assays
using some of the biomarkers for diagnosing AD.
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Other labs could test these biomarkers in a clinical setting and check for further replication
and reproducibility.
Potential treatments could be found, once useful pathways are found, using these biomarkers
to guide enrollment into those investigations.
Additionally, it would be important to develop programs or use new software to allow faster
and more effective data analysis and statistical comparisons. Likewise, better search engines to
facilitate peptide identification would be valuable, especially those that take more sophisticated
approaches to peptide sequencing. My sample preparation method uses acetonitrile precipitation
eliminating most proteins and hence, most peptide identifications rely on sequencing and can be
complex and not typically successful on current search engines. Additionally, most online search
engines cannot handle post-translational modifications or oxidations that are encountered in my
studies. This has required me to do manual de novo sequencing routinely even for short peptides,
and the process is very time consuming. When there are many peptides to be sequenced for a
project, a good de novo sequencing program would be very useful.
With the computational proteomics expertise of Dr. Prince and programming guidance from
my husband (Jigar B. Shah), I wrote a program, which employed de novo sequencing, to
overcome weaknesses of the online search engines like MASCOT. With additional work, this
could help in better and faster identification of peptides. However, better peak normalization
procedures would be required to allow such a program to succeed as well as the ability to
account for more complex post-translational modifications. Efforts could be made in this
direction in the future as well as in developing programs that can pick out peaks, compare them
and calculate the differences between cases and controls statistically.
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CHAPTER 7 - APPENDIX

7.1 Quadrupole Mass Spectrometer

7.1.1. Equations of Motion
The voltage distribution (potential) experienced by ions as they enter the mass analyzer
hinges on two factors: the shape of the electrodes and the time dependent nature of the voltage
applied to the electrodes, which can be illustrated as follows:
𝜙𝜙 = (𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔)

𝑥𝑥 2 − 𝑦𝑦 2
2𝑟𝑟0 2

where UDC is the magnitude of the DC voltage applied, VRF is the magnitude of the RF

voltage, ω is the angular frequency of the RF voltage (2πf), r0 is the distance from the center axis
(z axis) to any electrode and x and y are distances along the given coordinate axes.
The electric field at any point of time within the electrodes can be calculated by taking the
partial derivative of the potential defined above as a function of the distance along any of the
coordinate axes.
𝐸𝐸𝑥𝑥 = −
𝐸𝐸𝑦𝑦 = −
𝐸𝐸𝑧𝑧 = −

𝑑𝑑Φ
𝑥𝑥
= −(𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔) 2
𝑑𝑑𝑥𝑥
𝑟𝑟0
𝑑𝑑Φ
𝑦𝑦
= (𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔) 2
𝑑𝑑𝑑𝑑
𝑟𝑟0

𝑑𝑑Φ
=0
𝑑𝑑𝑑𝑑

Acceleration of the ion along the coordinate axes can be defined as the rate of change of

velocity (which itself is the rate of change of displacement of the ion along the axes) of the ion
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along the coordinate axes. That’s why it can be defined as:
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑 2 𝑥𝑥
𝑎𝑎𝑥𝑥 =
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡 2
𝑎𝑎𝑦𝑦 =

𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑 2 𝑦𝑦
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡 2

By Newton’s law of motion,

𝐹𝐹 = 𝑚𝑚𝑚𝑚

𝐹𝐹𝑥𝑥 = 𝑚𝑚𝑎𝑎𝑥𝑥 = 𝑚𝑚

𝑑𝑑2 𝑥𝑥
𝑑𝑑𝑡𝑡 2

𝑑𝑑 2 𝑦𝑦
𝐹𝐹𝑦𝑦 = 𝑚𝑚𝑎𝑎𝑦𝑦 = 𝑚𝑚 2
𝑑𝑑𝑡𝑡

The force exerted on the ions can also be defined as the product of the charge of the ion (e)

and the magnitude of the electric field (E).
𝐹𝐹 = 𝐸𝐸𝐸𝐸

𝐹𝐹𝑥𝑥 = −(𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔)
𝐹𝐹𝑦𝑦 = (𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔)
𝐹𝐹𝑧𝑧 = 0

𝑒𝑒𝑒𝑒
𝑟𝑟0 2

𝑒𝑒𝑒𝑒
𝑟𝑟0 2

𝑑𝑑2 𝑥𝑥
𝑒𝑒𝑒𝑒
𝑚𝑚 2 = −(𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔) 2
𝑑𝑑𝑡𝑡
𝑟𝑟0
𝑑𝑑2 𝑥𝑥
𝑒𝑒𝑒𝑒
= −(𝑈𝑈𝐷𝐷𝐷𝐷 + 𝑉𝑉𝑅𝑅𝑅𝑅 cos 𝜔𝜔𝜔𝜔)
2
𝑑𝑑𝑡𝑡
𝑚𝑚𝑚𝑚0 2

𝑑𝑑2 𝑥𝑥
𝑒𝑒𝑒𝑒
(𝑈𝑈
+
+
𝑉𝑉
cos
𝜔𝜔𝜔𝜔)
=0
𝐷𝐷𝐷𝐷
𝑅𝑅𝑅𝑅
𝑑𝑑𝑡𝑡 2
𝑚𝑚𝑚𝑚0 2
Similarly,

𝑑𝑑2 𝑦𝑦
𝑒𝑒𝑒𝑒
(𝑈𝑈
−
+
𝑉𝑉
cos
𝜔𝜔𝜔𝜔)
=0
𝐷𝐷𝐷𝐷
𝑅𝑅𝑅𝑅
𝑑𝑑𝑡𝑡 2
𝑚𝑚𝑚𝑚0 2
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𝑑𝑑2 𝑧𝑧
=0
𝑑𝑑𝑡𝑡 2

The solutions to the differential equations above give us a complete description of the

trajectory of any ion in terms of each ion’s initial conditions. As can be seen, the voltages of the
electrodes do not affect the acceleration of the ion along the z-axis. If we define parameters a and
q such that
𝑎𝑎 =
𝑞𝑞 =

4𝑒𝑒𝑈𝑈𝐷𝐷𝐷𝐷
𝜔𝜔 2 𝑚𝑚𝑚𝑚0 2

2𝑒𝑒𝑉𝑉𝑅𝑅𝑅𝑅
𝜔𝜔 2 𝑚𝑚𝑚𝑚0 2

the differential equations can be restated now as
𝑑𝑑2 𝑥𝑥 𝜔𝜔2
(𝑎𝑎 + 2𝑞𝑞 cos 𝜔𝜔𝜔𝜔)𝑥𝑥 = 0
+
4
𝑑𝑑𝑡𝑡 2

𝑑𝑑2 𝑦𝑦 𝜔𝜔2
(𝑎𝑎 + 2𝑞𝑞 cos 𝜔𝜔𝜔𝜔)𝑦𝑦 = 0
−
𝑑𝑑𝑡𝑡 2
4

These equations can be transformed into the accepted form of Mathieu’s differential equation

by doing the following change of variables:
𝜉𝜉 =

𝜔𝜔𝜔𝜔
2

Mathieu’s equation consists of a second derivative of the distances along the coordinate axes

as a function of ξ that can be calculated using the chain rule:
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
=
� � (𝑤𝑤ℎ𝑒𝑒𝑒𝑒𝑒𝑒 𝑢𝑢 𝑖𝑖𝑖𝑖 𝑥𝑥 𝑜𝑜𝑜𝑜 𝑦𝑦)
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑2 𝑢𝑢
𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
=
� � ��
2
𝑑𝑑𝜉𝜉
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑

By the product rule of derivatives,
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𝑑𝑑2 𝑢𝑢
𝑑𝑑2 𝑡𝑡 𝑑𝑑𝑑𝑑
𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
=
�
�
+
� �
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝜉𝜉 2
𝑑𝑑𝜉𝜉 2 𝑑𝑑𝑑𝑑
Based on the definition of ξ,

𝜉𝜉 =
𝑡𝑡 =

𝜔𝜔𝜔𝜔
2

2𝜉𝜉
𝜔𝜔

𝑑𝑑𝑑𝑑
2
=
𝑑𝑑𝑑𝑑
𝜔𝜔

𝑑𝑑2 𝑡𝑡
=0
𝑑𝑑𝜉𝜉 2

Therefore, the equation now becomes

𝑑𝑑2 𝑢𝑢
2 𝑑𝑑 𝑑𝑑𝑑𝑑
=
� �
2
𝑑𝑑𝜉𝜉
𝜔𝜔 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑

We can calculate the right part of the equation above as follows:

𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
=
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

𝑑𝑑𝑑𝑑
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑 𝑑𝑑𝑑𝑑
� �=
� �
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

By quotient rule of derivatives,

𝑑𝑑𝑑𝑑 𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑 𝑑𝑑𝑑𝑑
� �−
� �
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 2
� �
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑 2 𝑢𝑢 𝑑𝑑𝑑𝑑 𝑑𝑑 2 𝑡𝑡
−
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝜉𝜉 2
𝑑𝑑𝑑𝑑 𝑑𝑑𝜉𝜉 2
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 2
� �
𝑑𝑑𝑑𝑑
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𝑑𝑑2 𝑡𝑡

Since 𝑑𝑑𝜉𝜉2 = 0
𝑑𝑑 𝑑𝑑𝑑𝑑
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑

𝑑𝑑𝑑𝑑 𝑑𝑑 2 𝑢𝑢
𝑑𝑑𝑑𝑑 𝑑𝑑𝜉𝜉 2
𝑑𝑑𝑑𝑑 2
�
𝑑𝑑𝑑𝑑

�

𝑑𝑑 2 𝑢𝑢
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑ξ2
� �=
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑

𝑑𝑑 2 𝑢𝑢 𝑑𝑑𝑡𝑡 2
�
�
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡 2 𝑑𝑑𝜉𝜉 2
� �=
𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑑𝑑
𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑 2 𝑢𝑢 𝑑𝑑𝑑𝑑
� �=
� �
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡 2 𝑑𝑑𝑑𝑑
2 𝑑𝑑 2 𝑢𝑢
𝑑𝑑 𝑑𝑑𝑑𝑑
� �=
𝑑𝑑𝑑𝑑 𝑑𝑑𝑑𝑑
𝜔𝜔 𝑑𝑑𝑡𝑡 2

Therefore, the final equation now becomes

𝑑𝑑2 𝑢𝑢
4 𝑑𝑑 2 𝑢𝑢
= 2 2
𝑑𝑑𝜉𝜉 2
𝜔𝜔 𝑑𝑑𝑡𝑡

𝑑𝑑2 𝑢𝑢
4
𝜔𝜔2
(𝑎𝑎 + 2𝑞𝑞 cos 𝜔𝜔𝜔𝜔)𝑢𝑢�
= 2 �−
𝑑𝑑𝜉𝜉 2
4
𝜔𝜔
𝑑𝑑2 𝑢𝑢
+ (𝑎𝑎 + 2𝑞𝑞 cos 𝜔𝜔𝜔𝜔)𝑢𝑢 = 0
𝑑𝑑𝜉𝜉 2

which is the canonical form of Mathieu’s equation (Miller and Denton 1986).

7.1.2 Stability Diagram
An examination of the solutions of Mathieu’s equations indicates that stable oscillatory
trajectories can be established with certain values of a and q, which will allow ions to safely pass
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through the quadrupole mass analyzer. All other values will lead to unstable trajectories that
cause the ions to be filtered out. Since Mathieu’s equations are represented in terms of two
variables, a simple graph can be plotted showing stable solutions of the equation for values of a
and q, making it easier to visualize. Figure 7.1 shows the stable solutions of Mathieu’s equations
in the X direction when a and q are positive. This basically shows the values of a and q for which
the ions will have a stable path through the analyzer in the X-Z plane. Figure 7.2 shows the
solutions in the Y direction for negative values of a and q, which indicates the safe passage of
ions along the Y-Z plane. As we can see, both the graphs are mirror images of each other.
Overlaying the two graphs gives us solutions that would allow safe trajectories for ions in all
directions. Summarily, the values of a and q that lie at the intersection of the two graphs (Figure
7.3) will give us solutions that would let the ions pass through the filter safely.
Since quadrupole mass analyzers are used at low voltages, I am more interested in the lower
values of a and q in the stable regions in Figure 7.3. This figure shows a magnified image of the
stability region of the overlaid graph. Every mass has its own a and q values under a set of
operating conditions. Thus, masses can be plotted on the stability region of a and q. This forms
the basis of the mass filtering mechanism, since values of a and q can be chosen such that only
ions within a range of masses are allowed stable trajectories across the analyzer. Consider two
ions with masses m0 and m1. If conditions are chosen such that for m0 the values are a0 and q0,
m1 can be calculated taking the ratio of as and qs as shown in the following equations.
8𝑒𝑒𝑒𝑒� 𝔴𝔴2 𝑟𝑟 2
𝑎𝑎1
𝑚𝑚0
𝑚𝑚0
𝑚𝑚1
0
=
=
⟶ 𝑎𝑎1 = � � 𝑎𝑎0
8𝑒𝑒𝑒𝑒� 𝔴𝔴2 𝑟𝑟 2
𝑎𝑎0
𝑚𝑚1
𝑚𝑚1
𝑚𝑚0
0
4𝑒𝑒𝑒𝑒� 𝔴𝔴2 𝑟𝑟 2
𝑞𝑞1
𝑚𝑚0
𝑚𝑚0
𝑚𝑚1
0
=
=
⟶ 𝑞𝑞1 = � � 𝑞𝑞0
4𝑒𝑒𝑒𝑒� 𝔴𝔴2 𝑟𝑟 2
𝑞𝑞0
𝑚𝑚1
𝑚𝑚1
𝑚𝑚0
0

170

Figure 7.1. Stability diagram showing stable solutions of Mathieu’s equation in the X direction.
Reprinted from (Group 1998) with permission. ©University of Richmond, 1998.
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Figure 7.2. Stability diagram showing stable solutions of Mathieu’s equation in the Y direction.
Reprinted from (Group 1998) with permission. ©University of Richmond, 1998.
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Figure 7.3. Overlaid stability diagram showing the stable regions at the intersection points.
Reprinted from (Group 1998) with permission. ©University of Richmond, 1998.
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This means that all masses can be represented by a straight line starting from (0,0) in the a
and q graph. The slope of that line will indicate the filtering of masses of ions that would be
allowed to pass. Figure 7.4 shows a magnified image of the stability region in the a and q graph
with three different lines indicating different values of DC and AC potentials applied to the
quadrupole. As one can see, the top line would not allow any ions through, since none of the
masses lie within the green stability region. The second and third lines would allow masses to
pass through that lie in the green stability region.

7.2 Time-of-Flight Mass Spectrometer
The time of flight mass spectrometer’s entry point consists of two conducting plates. Let us
assume that they are separated by distance d. If voltage is applied to one of the plates, an electric
field will be created. Now, if we pass ions through this electric field, the potential energy of an
ion is equal to the charge of the ion (q) times the strength of the electric field at the point at
which it was created (U).
𝐸𝐸𝑃𝑃𝑃𝑃 = 𝑞𝑞𝑞𝑞

The charge of an ion is equal to the product of an integer number z of electron charges e.

𝑞𝑞 = 𝑒𝑒𝑒𝑒

Therefore, the potential energy of the ion now becomes

𝐸𝐸𝑃𝑃𝑃𝑃 = 𝑒𝑒𝑒𝑒𝑒𝑒

Because there is a field gradient between the two plates and like charges repel each other, the

ion will experience a push towards the grounded plate. Due to this push, the potential energy of
the ion is converted into kinetic energy that is defined by
𝐸𝐸𝐾𝐾𝐾𝐾 =

1
𝑚𝑚𝑣𝑣 2
2
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where m is the mass of the ion and v is the velocity imparted on the ion. Because potential
energy of the ion is converted into kinetic energy, I can equate both equations and find the value
for the time-of-flight of the ion:
𝐸𝐸𝑃𝑃𝑃𝑃 = 𝐸𝐸𝐾𝐾𝐾𝐾

𝑒𝑒𝑒𝑒𝑒𝑒 =
𝑣𝑣 2 =

1
𝑚𝑚𝑣𝑣 2
2

2𝑒𝑒𝑒𝑒𝑒𝑒
𝑚𝑚

2𝑒𝑒𝑒𝑒𝑒𝑒
𝑣𝑣 = �
𝑚𝑚

𝑧𝑧
𝑣𝑣 = √2𝑒𝑒𝑒𝑒�
𝑚𝑚

Thus, it is seen that the velocity imparted to the ion because of the voltage applied is

inversely proportional to the square root of the mass of the ion. If the grounded plate is a wire
mesh or has a slit in it for the ion to pass through, the ion will pass through and achieve a
velocity v defined above. After passing through the grounded plate, the ion is in a field-free zone
and drifts at a constant velocity. Therefore, the time required for the ion to travel a distance D
post acceleration can be calculated as follows:
𝑡𝑡𝑇𝑇𝑇𝑇𝑇𝑇 =
𝑡𝑡𝑇𝑇𝑇𝑇𝑇𝑇 =
𝑡𝑡𝑇𝑇𝑇𝑇𝑇𝑇 =

𝐷𝐷
𝑣𝑣

𝐷𝐷

𝑧𝑧
√2𝑒𝑒𝑒𝑒�𝑚𝑚
𝐷𝐷

𝑚𝑚
√2𝑒𝑒𝑒𝑒 𝑧𝑧
�

Thus, the time required for an ion to travel in a field-free region is directly proportional to the

square root of the mass-to-charge ratio of the ion (Figure 7.5).
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Figure 7.4. Magnified image of the stability region. Reprinted from (Group 1998) with permission.
©University of Richmond, 1998.
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Figure 7.5. Concept of time-of-flight mass spectrometer.
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